CN114276349B - 2-氨基喋啶酮类衍生物或其盐及其制备方法和用途 - Google Patents
2-氨基喋啶酮类衍生物或其盐及其制备方法和用途 Download PDFInfo
- Publication number
- CN114276349B CN114276349B CN202111514246.7A CN202111514246A CN114276349B CN 114276349 B CN114276349 B CN 114276349B CN 202111514246 A CN202111514246 A CN 202111514246A CN 114276349 B CN114276349 B CN 114276349B
- Authority
- CN
- China
- Prior art keywords
- amino
- ethyl
- methylfuran
- pteridin
- piperazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 49
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims abstract description 36
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims abstract description 17
- 229960005305 adenosine Drugs 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 14
- -1 trifluoromethoxy, difluoromethoxy Chemical group 0.000 claims description 296
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 208000018737 Parkinson disease Diseases 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 208000037487 Endotoxemia Diseases 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 108091006082 receptor inhibitors Proteins 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 108
- OOIPDYWPGUHUJW-UHFFFAOYSA-N 8h-pteridin-7-one Chemical compound C1=NC=NC2=NC(O)=CN=C21 OOIPDYWPGUHUJW-UHFFFAOYSA-N 0.000 description 98
- 238000005481 NMR spectroscopy Methods 0.000 description 73
- 238000006243 chemical reaction Methods 0.000 description 69
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 64
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 45
- 239000007787 solid Substances 0.000 description 40
- 238000004809 thin layer chromatography Methods 0.000 description 34
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 31
- 230000015572 biosynthetic process Effects 0.000 description 29
- 238000003786 synthesis reaction Methods 0.000 description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 22
- 239000012074 organic phase Substances 0.000 description 20
- 238000003756 stirring Methods 0.000 description 20
- 229910052757 nitrogen Inorganic materials 0.000 description 19
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 16
- 238000010898 silica gel chromatography Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 14
- 125000006413 ring segment Chemical group 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- 125000003118 aryl group Chemical group 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 229960000583 acetic acid Drugs 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 239000012362 glacial acetic acid Substances 0.000 description 8
- 125000001072 heteroaryl group Chemical group 0.000 description 8
- 238000007789 sealing Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 7
- TYEYBOSBBBHJIV-UHFFFAOYSA-M 2-oxobutanoate Chemical compound CCC(=O)C([O-])=O TYEYBOSBBBHJIV-UHFFFAOYSA-M 0.000 description 7
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 7
- LMJIDBVSSSPRII-UHFFFAOYSA-N (5-methylfuran-2-yl)boronic acid Chemical compound CC1=CC=C(B(O)O)O1 LMJIDBVSSSPRII-UHFFFAOYSA-N 0.000 description 6
- ZXWGHENZKVQKPX-UHFFFAOYSA-N 4,6-dichloropyrimidine-2,5-diamine Chemical compound NC1=NC(Cl)=C(N)C(Cl)=N1 ZXWGHENZKVQKPX-UHFFFAOYSA-N 0.000 description 6
- 102000009346 Adenosine receptors Human genes 0.000 description 6
- 108050000203 Adenosine receptors Proteins 0.000 description 6
- JADDQZYHOWSFJD-FLNNQWSLSA-N N-ethyl-5'-carboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 JADDQZYHOWSFJD-FLNNQWSLSA-N 0.000 description 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 6
- 229960003638 dopamine Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- UCRHFBCYFMIWHC-UHFFFAOYSA-N piperaquine Chemical compound ClC1=CC=C2C(N3CCN(CC3)CCCN3CCN(CC3)C=3C4=CC=C(C=C4N=CC=3)Cl)=CC=NC2=C1 UCRHFBCYFMIWHC-UHFFFAOYSA-N 0.000 description 6
- 229950006717 piperaquine Drugs 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 5
- 208000012661 Dyskinesia Diseases 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 230000001376 precipitating effect Effects 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- HNXQXTQTPAJEJL-UHFFFAOYSA-N 2-aminopteridin-4-ol Chemical compound C1=CN=C2NC(N)=NC(=O)C2=N1 HNXQXTQTPAJEJL-UHFFFAOYSA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 238000002619 cancer immunotherapy Methods 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- QQMMRUXVEWMQKW-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(C4)CC4N(C)C(C=C4)=CC=C4OC)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(C4)CC4N(C)C(C=C4)=CC=C4OC)=C2N=CC3=O)O1 QQMMRUXVEWMQKW-UHFFFAOYSA-N 0.000 description 3
- CDLLGGKJSXWQOF-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C4=CC=CC=C4)=C2N=CC3=O)O1 Chemical class CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C4=CC=CC=C4)=C2N=CC3=O)O1 CDLLGGKJSXWQOF-UHFFFAOYSA-N 0.000 description 3
- 229910004373 HOAc Inorganic materials 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical compound CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 3
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- TZRQZPMQUXEZMC-UHFFFAOYSA-N tert-butyl n-(2-bromoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCBr TZRQZPMQUXEZMC-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- VQKFNUFAXTZWDK-UHFFFAOYSA-N 2-Methylfuran Chemical compound CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- VRTAMKWPTWMVBS-NSHDSACASA-N 6-[[(3s)-oxolan-3-yl]oxymethyl]pyridine-2-carbonitrile Chemical compound N#CC1=CC=CC(CO[C@@H]2COCC2)=N1 VRTAMKWPTWMVBS-NSHDSACASA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 2
- 101710185931 Amine oxidase [flavin-containing] B Proteins 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- QIBRGLDKHPVWKT-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CC(C=C4)=CC=C4OC)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CC(C=C4)=CC=C4OC)=C2N=CC3=O)O1 QIBRGLDKHPVWKT-UHFFFAOYSA-N 0.000 description 2
- RXCSIZCSJRHPNW-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCC(CC4)CCN4C4=CC=CC=C4)=C2N=CC3=O)O1 Chemical class CC1=CC=C(C2=NC(N)=NC(N3CCC(CC4)CCN4C4=CC=CC=C4)=C2N=CC3=O)O1 RXCSIZCSJRHPNW-UHFFFAOYSA-N 0.000 description 2
- PKYVCRLAJNNEBJ-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCC4=CC=CC=C4)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCC4=CC=CC=C4)=C2N=CC3=O)O1 PKYVCRLAJNNEBJ-UHFFFAOYSA-N 0.000 description 2
- DYBIIASEQSAQKZ-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN4CCN(C)CC4)=C2N=CC3=O)O1 Chemical class CC1=CC=C(C2=NC(N)=NC(N3CCN4CCN(C)CC4)=C2N=CC3=O)O1 DYBIIASEQSAQKZ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000006378 Catechol O-methyltransferase Human genes 0.000 description 2
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 150000001543 aryl boronic acids Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004227 basal ganglia Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- 210000001009 nucleus accumben Anatomy 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- CSNFMBGHUOSBFU-UHFFFAOYSA-N pyrimidine-2,4,5-triamine Chemical compound NC1=NC=C(N)C(N)=N1 CSNFMBGHUOSBFU-UHFFFAOYSA-N 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- LZPZPHGJDAGEJZ-AKAIJSEGSA-N regadenoson Chemical compound C1=C(C(=O)NC)C=NN1C1=NC(N)=C(N=CN2[C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C2=N1 LZPZPHGJDAGEJZ-AKAIJSEGSA-N 0.000 description 2
- 229960003614 regadenoson Drugs 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- XDPCNPCKDGQBAN-BYPYZUCNSA-N (3s)-oxolan-3-ol Chemical compound O[C@H]1CCOC1 XDPCNPCKDGQBAN-BYPYZUCNSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- SYSZENVIJHPFNL-UHFFFAOYSA-N (alpha-D-mannosyl)7-beta-D-mannosyl-diacetylchitobiosyl-L-asparagine, isoform B (protein) Chemical compound COC1=CC=C(I)C=C1 SYSZENVIJHPFNL-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- DVQWNQBEUKXONL-UHFFFAOYSA-N 1-iodo-2-methoxybenzene Chemical compound COC1=CC=CC=C1I DVQWNQBEUKXONL-UHFFFAOYSA-N 0.000 description 1
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SQLZGKYMIUGRCL-UHFFFAOYSA-N 6-(bromomethyl)pyridine-2-carbonitrile Chemical compound BrCC1=CC=CC(C#N)=N1 SQLZGKYMIUGRCL-UHFFFAOYSA-N 0.000 description 1
- PSMJPIJDIKSKJT-NSHDSACASA-N 6-chloro-4-n-[[6-[[(3s)-oxolan-3-yl]oxymethyl]pyridin-2-yl]methyl]pyrimidine-2,4,5-triamine Chemical compound NC1=NC(Cl)=C(N)C(NCC=2N=C(CO[C@@H]3COCC3)C=CC=2)=N1 PSMJPIJDIKSKJT-NSHDSACASA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- LMHFDZUFYKYFMK-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CC(C=CC=C4)=C4OC)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CC(C=CC=C4)=C4OC)=C2N=CC3=O)O1 LMHFDZUFYKYFMK-UHFFFAOYSA-N 0.000 description 1
- FDPYKQOBHFUXAK-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CC(CC4)CCN4C4=CC=CC=C4)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CC(CC4)CCN4C4=CC=CC=C4)=C2N=CC3=O)O1 FDPYKQOBHFUXAK-UHFFFAOYSA-N 0.000 description 1
- BWRDLKUFCGFHSO-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CC4=CC(C(F)(F)F)=CC=C4)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CC4=CC(C(F)(F)F)=CC=C4)=C2N=CC3=O)O1 BWRDLKUFCGFHSO-UHFFFAOYSA-N 0.000 description 1
- YOLQTROSRYZZFQ-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CC4=CC(OC)=CC=C4)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CC4=CC(OC)=CC=C4)=C2N=CC3=O)O1 YOLQTROSRYZZFQ-UHFFFAOYSA-N 0.000 description 1
- KHYXCTKKSFTXSV-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CC4=CC=CC=C4)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CC4=CC=CC=C4)=C2N=CC3=O)O1 KHYXCTKKSFTXSV-UHFFFAOYSA-N 0.000 description 1
- KONIIWKRLZETBJ-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CC4=CC=CO4)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CC4=CC=CO4)=C2N=CC3=O)O1 KONIIWKRLZETBJ-UHFFFAOYSA-N 0.000 description 1
- WPABDQQUGWGFPI-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CC4CC4)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CC4CC4)=C2N=CC3=O)O1 WPABDQQUGWGFPI-UHFFFAOYSA-N 0.000 description 1
- RUMLPLQVEUPUTJ-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CC4CCCCC4)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CC4CCCCC4)=C2N=CC3=O)O1 RUMLPLQVEUPUTJ-UHFFFAOYSA-N 0.000 description 1
- CMWXSRYHPVUFTA-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCCC4=CC=CC=C4)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCCC4=CC=CC=C4)=C2N=CC3=O)O1 CMWXSRYHPVUFTA-UHFFFAOYSA-N 0.000 description 1
- MIBKLSWBYDFURE-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCCCC4=CC=CC=C4)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCCCC4=CC=CC=C4)=C2N=CC3=O)O1 MIBKLSWBYDFURE-UHFFFAOYSA-N 0.000 description 1
- GMFOJJKMBOYICL-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(C(CC4)C5)C4CN5C(C=C4)=CC=C4OC)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(C(CC4)C5)C4CN5C(C=C4)=CC=C4OC)=C2N=CC3=O)O1 GMFOJJKMBOYICL-UHFFFAOYSA-N 0.000 description 1
- QCGDCFVVNKBMQC-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(C)C(CC4)CN4C(C=C4)=CC=C4OC)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(C)C(CC4)CN4C(C=C4)=CC=C4OC)=C2N=CC3=O)O1 QCGDCFVVNKBMQC-UHFFFAOYSA-N 0.000 description 1
- LNZWNAQCCDTWHH-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CC4N(C)C(C=C4)=CC=C4OC)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CC4N(C)C(C=C4)=CC=C4OC)=C2N=CC3=O)O1 LNZWNAQCCDTWHH-UHFFFAOYSA-N 0.000 description 1
- BZOLKXSFTMRASS-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCC4C4=CC=CC=C4)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCC4C4=CC=CC=C4)=C2N=CC3=O)O1 BZOLKXSFTMRASS-UHFFFAOYSA-N 0.000 description 1
- VWRASBCGIZFJEJ-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C(F)=C4)=NC=C4OC)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C(F)=C4)=NC=C4OC)=C2N=CC3=O)O1 VWRASBCGIZFJEJ-UHFFFAOYSA-N 0.000 description 1
- UCYYPBQGUCEYAE-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=C4)=CC=C4F)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=C4)=CC=C4F)=C2N=CC3=O)O1 UCYYPBQGUCEYAE-UHFFFAOYSA-N 0.000 description 1
- QQPOSZVIQBIWSZ-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=C4)=CC=C4OC(F)(F)F)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=C4)=CC=C4OC(F)(F)F)=C2N=CC3=O)O1 QQPOSZVIQBIWSZ-UHFFFAOYSA-N 0.000 description 1
- WFWDHIJIPMMNOR-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=C4)=CC=C4OC(F)F)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=C4)=CC=C4OC(F)F)=C2N=CC3=O)O1 WFWDHIJIPMMNOR-UHFFFAOYSA-N 0.000 description 1
- CPRYSHYEBNFCPG-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=C4)=CC=C4OC)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=C4)=CC=C4OC)=C2N=CC3=O)O1 CPRYSHYEBNFCPG-UHFFFAOYSA-N 0.000 description 1
- WALHSXGJSVIXLF-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=C4)=CC=C4OC4=CC=CC=C4)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=C4)=CC=C4OC4=CC=CC=C4)=C2N=CC3=O)O1 WALHSXGJSVIXLF-UHFFFAOYSA-N 0.000 description 1
- INHFBANAGPCJPP-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=C4)=NC=C4OC)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=C4)=NC=C4OC)=C2N=CC3=O)O1 INHFBANAGPCJPP-UHFFFAOYSA-N 0.000 description 1
- OCQPYNZYCWMACM-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=CC(OCCOC)=C4)=C4F)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=CC(OCCOC)=C4)=C4F)=C2N=CC3=O)O1 OCQPYNZYCWMACM-UHFFFAOYSA-N 0.000 description 1
- PCTRWGZWJUJBDK-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=CC(OCCOC)=C4F)=C4F)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=CC(OCCOC)=C4F)=C4F)=C2N=CC3=O)O1 PCTRWGZWJUJBDK-UHFFFAOYSA-N 0.000 description 1
- AWEGKJSSGCYMGW-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=CC=C4)=C4F)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=CC=C4)=C4F)=C2N=CC3=O)O1 AWEGKJSSGCYMGW-UHFFFAOYSA-N 0.000 description 1
- LNUADNZCJAWAQE-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=CC=C4)=C4OC(F)(F)F)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=CC=C4)=C4OC(F)(F)F)=C2N=CC3=O)O1 LNUADNZCJAWAQE-UHFFFAOYSA-N 0.000 description 1
- KMPNQVQGQZWUNC-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=CC=C4)=C4OC)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=CC=C4)=C4OC)=C2N=CC3=O)O1 KMPNQVQGQZWUNC-UHFFFAOYSA-N 0.000 description 1
- OYVGMZHSCNUIMN-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=N4)=CC=C4OC)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C(C=N4)=CC=C4OC)=C2N=CC3=O)O1 OYVGMZHSCNUIMN-UHFFFAOYSA-N 0.000 description 1
- KWJKPLCPIYQPRR-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C4=C(C(F)(F)F)C=CC=C4)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C4=C(C(F)(F)F)C=CC=C4)=C2N=CC3=O)O1 KWJKPLCPIYQPRR-UHFFFAOYSA-N 0.000 description 1
- FYMPCXVJKLMVHT-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C4=CC(C(F)(F)F)=CC=C4)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C4=CC(C(F)(F)F)=CC=C4)=C2N=CC3=O)O1 FYMPCXVJKLMVHT-UHFFFAOYSA-N 0.000 description 1
- NTCGOBJORSMCGB-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C4=CC(F)=CC=C4)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C4=CC(F)=CC=C4)=C2N=CC3=O)O1 NTCGOBJORSMCGB-UHFFFAOYSA-N 0.000 description 1
- KIDMRUNJKGBUKP-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C4=CC(OC(F)(F)F)=CC=C4)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C4=CC(OC(F)(F)F)=CC=C4)=C2N=CC3=O)O1 KIDMRUNJKGBUKP-UHFFFAOYSA-N 0.000 description 1
- JBWNIBUJLPUDQQ-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C4=CC(OC)=CC=C4)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C4=CC(OC)=CC=C4)=C2N=CC3=O)O1 JBWNIBUJLPUDQQ-UHFFFAOYSA-N 0.000 description 1
- LZODKWZBYWMPIF-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C4=CC=C(C(F)(F)F)C=C4)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C4=CC=C(C(F)(F)F)C=C4)=C2N=CC3=O)O1 LZODKWZBYWMPIF-UHFFFAOYSA-N 0.000 description 1
- IARVGKXEVQVKOW-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C4CCCC4)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(CC4)CCN4C4CCCC4)=C2N=CC3=O)O1 IARVGKXEVQVKOW-UHFFFAOYSA-N 0.000 description 1
- SQDROIWUHYEYDU-UHFFFAOYSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(CCC4)CCN4C(C=C4)=CC=C4OC)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(CCC4)CCN4C(C=C4)=CC=C4OC)=C2N=CC3=O)O1 SQDROIWUHYEYDU-UHFFFAOYSA-N 0.000 description 1
- CUZJYJCDTLGEOB-ROUUACIJSA-N CC1=CC=C(C2=NC(N)=NC(N3CCN(C[C@@H]4C5)[C@@H]5CN4C(C=C4)=CC=C4OC)=C2N=CC3=O)O1 Chemical compound CC1=CC=C(C2=NC(N)=NC(N3CCN(C[C@@H]4C5)[C@@H]5CN4C(C=C4)=CC=C4OC)=C2N=CC3=O)O1 CUZJYJCDTLGEOB-ROUUACIJSA-N 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- LKIIXSUVDSDCMG-INIZCTEOSA-N C[C@@H](C1)N(CCN2C(N=C(N)N=C3C4=CC=C(C)O4)=C3N=CC2=O)CCN1C(C=C1)=CC=C1OC Chemical compound C[C@@H](C1)N(CCN2C(N=C(N)N=C3C4=CC=C(C)O4)=C3N=CC2=O)CCN1C(C=C1)=CC=C1OC LKIIXSUVDSDCMG-INIZCTEOSA-N 0.000 description 1
- QLDKSNSJQOSBLD-HNNXBMFYSA-N C[C@@H](C1)N(CCN2C(N=C(N)N=C3C4=CC=C(C)O4)=C3N=CC2=O)CCN1C(C=CC(OC)=C1)=C1F Chemical compound C[C@@H](C1)N(CCN2C(N=C(N)N=C3C4=CC=C(C)O4)=C3N=CC2=O)CCN1C(C=CC(OC)=C1)=C1F QLDKSNSJQOSBLD-HNNXBMFYSA-N 0.000 description 1
- BZMVDCSTGBTKTQ-DLBZAZTESA-N C[C@@H](C1)N(CCN2C(N=C(N)N=C3C4=CC=C(C)O4)=C3N=CC2=O)C[C@@H](C)N1C(C=C1)=CC=C1OC Chemical compound C[C@@H](C1)N(CCN2C(N=C(N)N=C3C4=CC=C(C)O4)=C3N=CC2=O)C[C@@H](C)N1C(C=C1)=CC=C1OC BZMVDCSTGBTKTQ-DLBZAZTESA-N 0.000 description 1
- HXTGWBZLGKWDCL-INIZCTEOSA-N C[C@@H](CN(CCN1C(N=C(N)N=C2C3=CC=C(C)O3)=C2N=CC1=O)CC1)N1C(C=C1)=CC=C1OC Chemical compound C[C@@H](CN(CCN1C(N=C(N)N=C2C3=CC=C(C)O3)=C2N=CC1=O)CC1)N1C(C=C1)=CC=C1OC HXTGWBZLGKWDCL-INIZCTEOSA-N 0.000 description 1
- LKIIXSUVDSDCMG-MRXNPFEDSA-N C[C@H](C1)N(CCN2C(N=C(N)N=C3C4=CC=C(C)O4)=C3N=CC2=O)CCN1C(C=C1)=CC=C1OC Chemical compound C[C@H](C1)N(CCN2C(N=C(N)N=C3C4=CC=C(C)O4)=C3N=CC2=O)CCN1C(C=C1)=CC=C1OC LKIIXSUVDSDCMG-MRXNPFEDSA-N 0.000 description 1
- HXTGWBZLGKWDCL-MRXNPFEDSA-N C[C@H](CN(CCN1C(N=C(N)N=C2C3=CC=C(C)O3)=C2N=CC1=O)CC1)N1C(C=C1)=CC=C1OC Chemical compound C[C@H](CN(CCN1C(N=C(N)N=C2C3=CC=C(C)O3)=C2N=CC1=O)CC1)N1C(C=C1)=CC=C1OC HXTGWBZLGKWDCL-MRXNPFEDSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000015592 Involuntary movements Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229920002472 Starch Chemical class 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 description 1
- CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical compound [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229940099424 adenocard Drugs 0.000 description 1
- 229940060202 adenoscan Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- QOTQFLOTGBBMEX-UHFFFAOYSA-N alpha-angelica lactone Chemical compound CC1=CCC(=O)O1 QOTQFLOTGBBMEX-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- KJHQVUNUOIEYSV-UHFFFAOYSA-N ethyl 3,3,3-trifluoro-2-oxopropanoate Chemical compound CCOC(=O)C(=O)C(F)(F)F KJHQVUNUOIEYSV-UHFFFAOYSA-N 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- 229940117360 ethyl pyruvate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000495 immunoinflammatory effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- IQVRBWUUXZMOPW-PKNBQFBNSA-N istradefylline Chemical compound CN1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1\C=C\C1=CC=C(OC)C(OC)=C1 IQVRBWUUXZMOPW-PKNBQFBNSA-N 0.000 description 1
- 229950009028 istradefylline Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WDWDWGRYHDPSDS-UHFFFAOYSA-N methanimine Chemical class N=C WDWDWGRYHDPSDS-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000007344 nucleophilic reaction Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 210000004205 output neuron Anatomy 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000037047 psychomotor activity Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于化学医药领域，涉及一种2‑氨基喋啶酮类衍生物或其盐及其制备方法和用途。这些化合物具有式(I)的结构，具有腺苷A2A受体(adenosine A2A receptor，A2AR)抑制活性，可用于制备治疗或预防与A2AR有关的疾病的药物。
Description
技术领域
本发明涉及化学医药领域，涉及一种2-氨基喋啶酮类衍生物或其盐及其制备方法和用途。
背景技术
腺苷作为内源性嘌呤核苷参与诸多的生理和病理过程：它是合成腺苷三磷酸(ATP)的必须前体、储存细胞能量的主要分子、合成核苷酸的重要代谢中间体。自1983年，四类亚型的腺苷受体(A1、A2A、A2B和A3)被克隆出来，胞外的腺苷正是通过调控这四类受体而发挥作用。腺苷受体属于一类G蛋白偶联受体(GPCR)，在体内分布广泛且发挥着不同作用，包括：血管舒张和缺血再灌注、血管生成、心律和循环、睡眠和唤醒、神经退行性疾病、炎症。靶向腺苷受体以期获得临床疗效由来已久也显而易见。腺苷本身作为一种仿制药(商品名Adenocard or Adenoscan)就在临床上用于治疗室上性心动过速，咖啡因在某些临床情况下也用于早产儿的呼吸暂停，很多临床药物(双嘧达莫、甲氨蝶呤)也很有可能是通过腺苷受体而发挥相应的作用。瑞加德松(商品名Lexiscan)被美国FDA批准为心肌血流灌注显影剂用以诊断冠状动脉疾病，伊曲茶碱(商品名Nouriast)在日本上市用于治疗早期帕金森综合征症状，这些更加证实了A2AR作为药物研发靶点的可能性。
在中枢神经系统(CNS)中，腺苷是一种有效的内源性神经调节剂，它控制许多神经递质的释放，因此涉及影响运动功能、睡眠、焦虑、疼痛和精神运动活动。大脑中主要的腺苷受体亚型是A1和A2A。腺苷A1受体高密度地分布于整个大脑。A1受体拮抗剂可降低癫痫发作阈值，并有潜在的促惊厥作用(e.g.,Cotter G,et al.,2008,J.Card.Fail.14:631-640)。A2A受体分布较为局限，在基底神经节纹状体(尾壳核、伏隔核、嗅结核)上高密度分布，与多巴胺D2受体一起位于纹状体输出神经元上。A2A受体在纹状体上地的离散分布及其对多巴胺D2受体的抑制作用，使A2A受体抑制剂展现出改善由神经退行性疾病，如帕金森氏症、阿尔茨海默症、亨廷顿氏舞蹈症和精神病引起的运动障碍等(e.g.,Rodrigo C,et al.,2008,Curr.Pharm.Des.14:1512-1524；Tuite P,et al.,2003,Expert Opin.Investig.Drugs12:1335-52；Popoli P.et al.,2002,J.Neurosci.22:1967-75)。
这些运动障碍通常可能是脑部病变的结果。涉及基底神经节导致运动障碍的疾病包括帕金森氏症、亨廷顿舞蹈症和威尔逊氏病。帕金森氏症的特征是黑质纹状体多巴胺能通路的逐步退化。纹状体多巴胺水平降低是导致运动障碍症状的原因。震颤，僵硬，运动障碍和体位变化是帕金森氏症的四个典型症状，但该疾病还与睡眠障碍，抑郁，焦虑，精神病，痴呆和整体认知能力下降有关(e.g.,Jankovic J,et al.,2008,J.Neural.Neurosurg.Psychiatry 79:368-376)。尽管可以使用药物减轻症状和/或减慢疾病的进程，帕金森氏症仍是一种进行性且目前无法治愈的疾病，并且没有明确的预防性治疗方法。当前的疗法是基于突触前末梢的多巴胺替代疗法，例如，通过使用L-DOPA(多巴胺前体)，直接刺激突触后D2受体或使用B型单胺氧化酶(MAO-B)或儿茶酚邻甲基转移酶(COMT)抑制代谢。尽管L-DOPA是治疗帕金森氏病的主要手段，但由于耐受性问题和诸多的不良反应，包括不自主运动和呕吐，且随着持续治疗，这种不良反应会变得越来越严重，对新疗法的需求仍然很高。为此，高度选择性的A2A受体拮抗剂已显示出其减轻与神经退行性疾病(如帕金森氏症)相关的运动症状的功效(e.g.,Shook and Jackson,2011,ACSChem.Neurosci.2:555-567)。
A2A受体拮抗剂也可能是成瘾治疗的潜在有用疗法。主要导致成瘾的药物(鸦片，可卡因，乙醇等)直接或间接调节神经元中的多巴胺信号传导，尤其是在伏隔核中。而伏隔核中含有高水平的A2A受体，腺苷信号通路激活显示出药物依赖性的增强，A2A受体拮抗剂可减少对成瘾性物质的渴望(e.g.,Stephen H,Macdonald C,2003,Crit.Rev.Neurobiol.15:235-274)。
近年来，癌症免疫治疗赢得学术界、工业界的青睐和各大商业资本的投入，毒性T淋巴细胞相关抗原4(CTLA-4)和程序性细胞死亡蛋白1(PD-1)的免疫药物也接连上市，免疫疗法必将成为继放化疗、靶向治疗之后的又一次革命，并开创肿瘤治疗的新局面。尽管免疫治疗在各类型癌症中取得一定成功，但肿瘤微环境(tumor microenvironment，TME)存在多种代偿性免疫抑制机制，导致免疫疗法的响应率偏低。腺苷信号通路在TME的免疫炎症调控中扮演重要角色，成为下调抗肿瘤免疫的关键负反馈回路。高浓度腺苷是TME的重要标志，激活表达在T淋巴细胞、NK细胞、单核细胞和树突状细胞等免疫细胞上的A2AR，从而抑制免疫细胞的先天性免疫功能和适应性免疫功能。A2AR拮抗剂可以阻断腺苷和A2AR结合从而逆转腺苷的免疫抑制作用，作为一种小分子免疫微环境调节剂(当前癌症免疫疗法几乎全是多肽、抗体和细胞药物)，A2AR拮抗剂可以激活抗肿瘤免疫，其作为癌症免疫治疗药物开发的潜力和市场价值巨大。
发明内容
1.一种通式(I)所示的化合物或其药学上可接受的盐或溶剂化物或其立体异构体。
其中
X选自O、S或者NH；
L选自C1-6亚烷基，-C1-6亚烷基-O-或者-C1-6亚烷基-N(R4)-；
A选自共价键，或者/>
B选自C1-6烷基，C3-8环烷基，含3-8个环原子的杂环烷基，芳基或杂芳基；
C选自芳基或杂芳基；
R1选自氢，卤素，羟基，氰基，三氟甲基，三氟甲氧基，二氟甲氧基，C1-8烷基，-O-C1-8烷基，-G1-O-C1-8烷基，-O-G1-O-C1-8烷基，-G1-O-G1-O-C1-8烷基，-C(O)R8，-C(O)OR8，-NR8R9，-C(O)NR8R9，-S(O2)R8，-S(O2)NR8R9，C3-8环烷基，-O-C3-8环烷基，含3-8个环原子的杂环烷基，-G1-O-含3-8个环原子的杂环烷基，芳基，杂芳基，-O-芳基或者-O-杂芳基中的一种或数种；
R2选自氢，卤素，羟基，氰基，C1-8烷基，-O-C1-8烷基，C3-8环烷基，含3-8个环原子的杂环烷基，芳基或杂芳基中的一种或几种；
R3选自氢，C1-8烷基，或者卤素取代的C1-8烷基；
R4选自氢，C1-8烷基，C3-8环烷基，含3-8个环原子的杂环烷基；
R5、R6各自独立地选自氢，C1-8烷基，C3-8环烷基，或者R5和R6桥接并与他们各自所连接的原子一起组成含有3-8个环原子的环烷基或杂环烷基；
R7选自氢，C1-8烷基，C3-8环烷基，含3-8个环原子的杂环烷基；
R8、R9各自独立地选自氢，C1-8烷基，C3-8环烷基，含3-8个环原子的杂环烷基；
G1选自C1-4亚烷基；
n1、n2选自0，1，2，3；
n3、n4选自1，2，3。
在一些优选的实施方案中，X为O。
在一些优选的实施方案中，R3为氢、CH3或CF3。
在一些优选的实施方案中，L为C1-6亚烷基；更为优选地，L为C1-4亚烷基。
在一些优选的实施方案中，A选自共价键，
在一些优选的实施方案中，B选自甲基，环丙基，环戊基，环己基，苯基，吡啶基，呋喃基，嘧啶基。
在一些优选的实施方案中，R1选自氢，卤素，氰基，三氟甲基，三氟甲氧基，二氟甲氧基，-O-C1-8烷基，-O-C1-4亚烷基-O-C1-8烷基，-C1-4亚烷基-O-C3-8环烷基，含3-8个环原子的杂环烷基，-C1-4亚烷基-O-含3-8个环原子的杂环烷基，-O-芳基中的一种或数种。
在一些优选的实施方案中，C选自呋喃基，苯基，吡唑基。
在一些优选的实施方案中，R2选自氢，卤素，氰基，CH3或CF3中的一种或几种；更为优选地，R2选自氢，氰基或-CH3中的一种或数种。
最优选地，本发明提供的2-氨基喋啶酮类化合物包括但不限于以下具体化合物实例：
1. 2-氨基-8-(4-甲氧基苯基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
2. 2-氨基-8-(3-甲氧基苯基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
3. 2-氨基-8-(2-甲氧基苯基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
4. 2-氨基-8-(3-氟苯基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
5. 2-氨基-4-(5-甲基呋喃-2-基)-8-(3-(三氟甲基)苄基)喋啶-7(8H)-酮
6. 3-((2-氨基-4-(5-甲基呋喃-2-基)-7-氧代喋啶-8(7H)-基)亚甲基)苯腈
7.(S)-2-氨基-4-(5-甲基呋喃-2-基)-8-((6-(((四氢呋喃-3-基)氧基)甲基)吡啶-2-基)亚甲基)喋啶-7(8H)-酮
8. 2-氨基-4-(5-甲基呋喃-2-基)-8-(吡啶-2-基亚甲基)喋啶-7(8H)-酮
9. 2-氨基-8-(呋喃-2-基亚甲基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
10. 2-氨基-8-(环己基亚甲基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
11. 2-氨基-8-(环丙亚甲基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
12. 2-氨基-8-苄基-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
13. 2-氨基-4-(5-甲基呋喃-2-基)-8-苯乙基喋啶-7(8H)-酮
14. 2-氨基-4-(5-甲基呋喃-2-基)-8-(3-苯基正丙基)喋啶-7(8H)-酮
15. 2-氨基-4-(5-甲基呋喃-2-基)-8-(4-苯基正丁基)喋啶-7(8H)-酮
16. 2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(4-甲基哌嗪-1-基)乙基)喋啶-7(8H)-酮
17. 2-氨基-8-(2-(4-环戊基哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
18. 2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(4-苯基哌嗪-1-基)乙基)喋啶-7(8H)-酮
19. 2-氨基-8-(2-(4-(2-甲氧基苯基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
20. 2-氨基-8-(2-(4-(3-甲氧基苯基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
21. 2-氨基-8-(2-(4-(4-甲氧基苯基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
22. 2-氨基-8-(2-(4-(2-氟苯基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
23. 2-氨基-8-(2-(4-(3-氟苯基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
24. 2-氨基-8-(2-(4-(4-氟苯基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
25. 2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(4-(2-(三氟甲基)苯基)哌嗪-1-基)乙基)喋啶-7(8H)-酮
26. 2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(4-(3-(三氟甲基)苯基)哌嗪-1-基)乙基)喋啶-7(8H)-酮
27. 2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(4-(4-(三氟甲基)苯基)哌嗪-1-基)乙基)喋啶-7(8H)-酮
28. 2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(4-(2-(三氟甲氧基)苯基)哌嗪-1-基)乙基)喋啶-7(8H)-酮
29. 2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(4-(3-(三氟甲氧基)苯基)哌嗪-1-基)乙基)喋啶-7(8H)-酮
30. 2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(4-(4-(三氟甲氧基)苯基)哌嗪-1-基)乙基)喋啶-7(8H)-酮
31.(S)-2-氨基-8-(2-(4-(4-甲氧基苯基)-2-甲基哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
32.(R)-2-氨基-8-(2-(4-(4-甲氧基苯基)-2-甲基哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
33.(S)-2-氨基-8-(2-(4-(4-甲氧基苯基)-3-甲基哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
34.(R)-2-氨基-8-(2-(4-(4-甲氧基苯基)-3-甲基哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
35. 2-氨基-8-(2-((2S,5R)-4-(4-甲氧基苯基)-2,5-二甲基哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
36. 2-氨基-8-(2-((1S,4S)-5-(4-甲氧基苯基)-2,5-二氮杂二环[2.2.1]庚烷-2-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
37. 2-氨基-8-(2-(3-(4-甲氧基苯基)-3,8-二氮杂二环[3.2.1]辛烷-8-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
38. 2-氨基-8-(2-(4-(4-甲氧基苯基)-1,4-二氮杂环庚烷-1-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
39. 2-氨基-4-(5-甲基呋喃-2-基)-8-((1-苯基哌啶-4-基)亚甲基)喋啶-7(8H)-酮
40. 2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(1-苯基哌啶-4-基)乙基)喋啶-7(8H)-酮
41. 2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(4-苯基哌啶-1-基)乙基)喋啶-7(8H)-酮
42. 2-氨基-8-(2-(3-((4-甲氧基苯基)(甲基)氨基)吡咯-1-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
43. 2-氨基-8-(2-((1-(4-甲氧基苯基)吡咯-3-基)(甲基)氨基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
44. 2-氨基-8-(2-(3-((4-甲氧基苯基)(甲基)氨基)氮杂环丁烷-1-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
45. 2-氨基-8-(2-(4-(2-氟-4-甲氧基苯基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
46. 2-氨基-8-(2-(4-(2,4-二氟苯基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
47. 2-氨基-8-(2-(4-(2-氟-4-甲氧基苯基)哌嗪-1-基)乙基)-6-甲基-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
48. 2-氨基-8-(2-(4-(2-氟苯基)哌嗪-1-基)乙基)-6-甲基-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
49. 2-氨基-8-(2-(4-(2-氟苯基)哌嗪-1-基)乙基)-6-三氟甲基-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
50. 2-(2-氨基-8-(2-(4-(2-氟苯基)哌嗪-1-基)乙基)-7-氧代-7,8-二氢喋啶-4-基)-6-甲基苯甲腈
51. 2-氨基-8-(2-(4-(2-氟苯基)哌嗪-1-基)乙基)-4-(1H-吡唑-4-基)喋啶-7(8H)-酮52. 2-氨基-8-(2-(4-(2-氟-4-(2-甲氧基乙氧基)苯基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
53. 2-氨基-8-(2-(4-(2,3-二氟-4-(2-甲氧基乙氧基)苯基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
54.(S)-2-氨基-8-(2-(4-(2-氟-4-甲氧基苯基)-2-甲基哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
55. 2-氨基-8-(2-(4-(6-甲氧基吡啶-3-基)哌嗪-1-基)乙基)-6-甲基-4-(5-甲基呋喃-2-基)蝶呤-7(8H)-酮
56. 2-氨基-8-(2-(4-(6-甲氧基吡啶-3-基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)蝶呤-7(8H)-酮
57. 2-氨基-8-(2-(4-(5-甲氧基吡啶-2-基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)蝶呤-7(8H)-酮
58. 2-氨基-8-(2-(4-(6-异丙氧基吡啶-3-基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)吡啶-7(8H)-酮
59. 2-氨基-8-(2-(4-(4-(二氟甲氧基)苯基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)蝶呤-7(8H)-酮
60. 2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(4-(嘧啶-5-基)哌嗪-1-基)乙基)蝶呤-7(8H)-酮
61. 2-氨基-8-(2-(4-(3-氟-5-甲氧基吡啶-2-基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)蝶呤-7(8H)-酮
62. 2-氨基-8-(2-(4-(5-(二氟甲氧基)-3-氟吡啶-2-基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)蝶呤-7(8H)-酮
63. 2-氨基-8-(2-(4-(5-(二氟甲氧基)-3-氟吡啶-2-基)哌嗪-1-基)乙基)-6-甲基-4-(5-甲基呋喃-2-基)蝶呤-7(8H)-酮
64. 2-氨基-8-(2-(4-(2-氟-4-(三氟甲氧基)苯基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)蝶呤-7(8H)-酮
65. 2-氨基-8-(2-(4-(2-氟-4-(三氟甲基)苯基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)蝶呤-7(8H)-酮
66. 2-氨基-8-(2-(4-(2-甲氧基嘧啶-5-基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)蝶呤-7(8H)-酮
67. 2-氨基-8-(2-(4-(5-(二氟甲氧基)-3-氟吡啶-2-基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)-6-(三氟甲基)蝶呤-7(8H)-酮
68. 2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(4-(4-苯氧基苯基)哌嗪-1-基)乙基)蝶呤-7(8H)-酮
本发明还提供了一种制备上述2-氨基喋啶酮类化合物的方法，包括以下合成方案：
反应条件：a)Et3N，Sec-BuOH，105℃，24h；b)HOAc，EtOH，80℃，4～6h；c)Pd(PPh3)4，Na2CO3，dioxane/H2O，95℃，12h。
Scheme 1代表了具有化学通式(I)的部分化合物的通用合成路线，起始原料1.1与取代亚甲基胺试剂通过亲核反应取代得到6-氯-N4-取代基嘧啶-2，4，5三胺中间体1.2，然后与乙醛酸乙酯通过关环得到中间体1.3，最后与相应的芳基硼酸或硼酸酯试剂通过Suzuki-Miyaura反应得到终产物1.4。
反应条件：a)Pd2(dba)3，2-二环己基膦-2'，6'-二异丙氧基-1,1'-联苯，toluene，105℃，24h；b)①2M HCl in EA，MeOH/EA，25℃，16h；②DIPEA，CH3CN，75℃，24h；c)①2M HClin EA，MeOH/EA，25℃，10h；②Et3N，Sec-BuOH，105℃，24h；d)HOAc，EtOH，80℃，4～6h；e)Pd(PPh3)4，Na2CO3，dioxane/H2O，95℃，12h。
Scheme 2代表了具有化学通式(I)的部分化合物的通用合成路线，起始原料2.1与相应的Boc保护的二胺试剂通过钯催化的碳氮偶联反应得到中间体2.2，然后酸性条件脱去Boc保护基并与相应的卤代物通过亲核取代反应得到中间体2.3，再经酸性条件脱去Boc保护基并与2,5-二氨基-4,6-二氯嘧啶通过亲核取代反应得到中间体2.4，然后与乙醛酸乙酯通过关环得到中间体2.5，最后与相应的芳基硼酸或硼酸酯试剂通过Suzuki-Miyaura反应得到终产物2.6。
除非另有说明，上述合成方案中所述基团、术语的含义与通式I化合物中的含义相同。
上述合成方案只是列举了本发明中部分化合物的制备方法，按照本领域的公知技术，技术人员在上述合成方案的基础上，采用类似的方法也可合成本发明的化合物。
本发明所述的“化合物”，包括所有立体异构体、几何异构体、互变异构体和同位素。
本发明所述的“化合物”，可以是不对称的，例如，具有一个或多个立体异构体。除非另有说明，所有立体异构体都包括，如对映异构体和非对映异构体。本发明中含有不对称碳原子的化合物，可以光学活性纯的形式或外消旋形式被分离出来。光学活性纯的形式可以从外消旋混合物拆分，或通过使用手性原料或手性试剂合成。
本发明所述的“化合物”，还包括互变异构体形式。互变异构体形式来源于一个单键与相邻的双键交换并一起伴随一个质子的迁移。
本发明还包括所有同位素的原子，无论是在中间体或最后的化合物。同位素的原子包括具有相同的原子数、但不同质量数的。例如，氢的同位素包括氘和氚。
本发明中，除特殊说明外，所用的术语具有如下含义：
术语“卤素”是指氟、氯、溴或碘，优选氟或氯。
术语“氰基”，指-CN。
术语“羟基”，指-OH。
术语“烷基”，指由碳原子和氢原子组成的直链或支链的饱和烃基团，如C1-C20烷基，优选为C1-C6烷基，例如甲基、乙基、丙基(包括正丙基和异丙基)、丁基(包括正丁基、异丁基、仲丁基或叔丁基)、戊基(包括正戊基、异戊基、新戊基)、正己基、2-甲基己基等。所述烷基可以是非取代的、或是被一个或多个取代基所取代，取代基包括但不限于烷基、烷氧基、氰基、羟基、羰基、羧基、芳基、杂芳基、氨基、卤素、磺酰基、亚磺酰基、磷酰基。
术语“亚烷基”，指烷基失去一个氢原子所得到的二价基团，其中烷基如上定义。，优选为C1-C4亚烷基，例如亚甲基、亚乙基、亚丙基、亚丁基。取代基包括但不限于烷基、烷氧基、氰基、羟基、羰基、羧基、芳基、杂芳基、氨基、卤素、磺酰基、亚磺酰基、磷酰基。
术语“环烷基”，指全部为碳的单环、稠合、螺环或桥环的环，如环丙基、环丁基、环戊基、环戊烯基、环己基、螺[3.4]辛烷基、二环[3.1.1]己烷基。
术语“杂环烷基”，指含1个或多个N、O或S的杂原子的单环或稠合的环。典型地为含1个或多个N、O或S的杂原子的5-6元杂环基，例如四氢呋喃基、哌嗪基、吗啉基、哌啶基、吡咯烷基及其衍生物。
术语“芳基”，指具有完全共轭的π电子体系的全碳单环或稠合环，通常具有6-14个碳原子，优选具有6-12个碳原子，最优选具有6个碳原子。芳基可以是非取代的、或被一个或多个取代基所取代，取代基包括但不限于烷基、烷氧基、氰基、羟基、羰基、羧基、芳基、芳烷基、氨基、卤素、磺酰基、亚磺酰基、磷酰基。非取代的芳基的实例包括但不限于苯基、萘基和蒽基。
术语“杂芳基”是指5-12个环原子的单环或稠合环,其中含有1-4个选自N、O、S的环原子，其余环原子为C，且具有完全共轭的π-电子体系，包括但不限于吡咯基、呋喃基、噻吩基、咪唑基、噁唑基、异噁唑基、吡唑基、吡啶基、嘧啶基、吡嗪基、哒嗪基、喹啉基、异喹啉基、三唑基、四氢吡咯基。杂芳基可以是非取代的或取代的，所述的取代基包括但不限于烷基、烷氧基、芳基、芳烷基、氨基、卤素、羟基、氰基、硝基、羰基和杂脂环基。
术语“共价键”，指原子间通过共用电子对所形成的相互作用。“治疗”意味着对哺乳动物体内疾病的任何治疗，包括：(1)防止疾病，即造成临床疾病的症状不发展；(2)抑制疾病，即阻止临床症状的发展；(3)减轻疾病，即造成临床症状的消退。
本发明还提供了一种药物组合物，包含如前所述的化合物或其药学上可接受的盐或溶剂化物作为活性成份，以及一种或多种药学上可接受的载体。
本发明所述的“药物组合物”，指一种或多种本发明的化合物或其盐或溶剂化物与在本领域中通常接受的用于将生物活性化合物输送至有机体(例如人)的载体的制剂。药物组合物的目的是有利于对有机体给药输送。
术语“药学上可接受的载体”，指与活性成份共同给药的、且有利于活性成份给药的物质，包括但不限于国家食品药品监督管理局许可的可接受的用于人或动物(例如家畜)的任何助流剂、增甜剂、稀释剂、防腐剂、染料/着色剂、矫味增强剂、表面活性剂、润湿剂、分散剂、崩解剂、助悬剂、稳定剂、等渗剂、溶剂或乳化剂。例如包括但不限于碳酸钙、磷酸钙、各种糖和各类淀粉、纤维素衍生物、明胶、植物油和聚乙二醇。
本发明所述的药物组合物，可配制成固态、半固态、液态或气态制剂，如片剂、丸剂、胶囊剂、粉剂、颗粒剂、膏剂、乳剂、悬浮剂、溶液剂、栓剂、注射剂、吸入剂、凝胶剂、微球及气溶胶等等。
本发明所述的药物组合物，可以采用本领域熟知的方法制造，如常规的混合法、溶解法、制粒法、制糖衣药丸法、磨细法、乳化法、冷冻干燥法等。
本发明所述的化合物或其药学上可接受的盐或其药物组合物的给药途径，包括但不限于口服、直肠、透黏膜、经肠给药，或者局部、经皮、吸入、肠胃外、舌下、阴道内、鼻内、眼内、腹膜内、肌内、皮下、静脉内给药。优选的给药途径是口服给药。
对于口服给药，可以通过将活性化合物与本领域熟知的药学上可接受的载体混合，来配制该药物组合物。这些载体能使本发明的化合物被配制成片剂、丸剂、锭剂、糖衣剂、胶囊剂、液体、凝胶剂、浆剂、悬浮剂等，以用于对患者的口服给药。例如，用于口服给药的药物组合物，可采用如下方式获得片剂：将活性成分与一种或多种固体载体合并，如果需要将所得混合物制粒，并且如果需要加入少量的赋形剂加工成混合物或颗粒，以形成片剂或片芯。片芯可与任选适合肠溶的包衣材料结合，加工成更有利于有机体(例如人)吸收的包衣制剂形式。
本发明还提供了一种如前所述的化合物或其药学上可接受的盐或溶剂化物，或前述药物组合物在制备腺苷A2AR抑制剂方面的应用。
本发明同时还提供了一种如前所述的化合物或其药学上可接受的盐或或溶剂化物或它们的药物组合物作为腺苷A2AR抑制剂在制备用于治疗或预防与A2AR有关的疾病的药物中的用途。
本发明化合物的药学上可接受的盐包括通过碱性和无机酸或有机酸反应形成的常规无毒盐。即采用化合物的游离碱，与无机或有机酸成盐反应进行。无机或有机酸可选自盐酸、硫酸、硝酸、氢氟酸、氢溴酸、甲酸、乙酸、苦味酸、柠檬酸、马来酸、甲烷磺酸、三氟甲烷磺酸、乙烷磺酸、对甲苯磺酸等。
如果发明化合物为酸性的，则适当的“药学上可接受的盐”指通过药学上可接受的无毒碱包括无机碱及有有机碱制备的盐。可选自铝盐、铵盐、锂盐、镁盐、钠盐等。特别优选铵盐、钙盐、镁盐、钾盐和钠盐。得自药学上可接受的有机无毒碱的盐，所述碱包括伯胺、仲胺和叔胺的盐，取代的胺包括天然存在的取代胺、环状胺及碱性离子交换树脂例如精氨酸、甜菜碱和咖啡因等。
优选的，前述与A2AR有关的疾病选自癌症(cancer)、帕金森病(Parkinson’sdisease)、肌萎缩性侧束硬化症(amyotrophic lateral sclerosis；ALS)、冠状动脉疾病(coronary artery disease)、轻度认知障碍(mild cognitive impairment)、多发性硬化(mμLtiple sclerosis)、心包性假性肝硬变(Pick’s disease)、类风湿性关节炎(rheumatoid arthritis)、双相型障碍(bipolar disorder)、实验性内毒素血症(experimental endotoxemia)、及精神分裂症(schizophrenia)或前述疾病组合。
本发明提供了一类具有通式(I)结构的2-氨基喋啶-7(8H)-酮类衍生物。经研究发现，该类化合物可有效抑制腺苷A2A受体，从而调节免疫微环境中胞内环磷酸腺苷(cAMP)的水平，调控机体的免疫生理反应，可作为治疗或预防与A2AR有关疾病的药物。
除在文献中已知的或在实验程序中例证的标准方法外，可采用如下列方案中显示的反应制备本发明化合物。因此，下列说明性方案是为说明的目的而不是局限于所列化合物或任何特定的取代基。方案中显示的取代基数目并不必需要符合权利要求中所用的数目，且为清楚起见，显示单取代基连接到本专利结构式的定义允许有多取代基的化合物。
具体实施方式
以下是本发明的具体实施例，对本发明的技术方案做进一步的描述，但是本发明的保护范围并不限于这些实施例。凡是不背离本发明构思的改变或等同替代均包括在本发明的保护范围之内。
本发明提供的目标化合物制备方法中，柱层析色谱采用乳山太阳干燥剂有限公司生产的硅胶(300-400目)；薄层色谱采用GF254(0.25毫米)；核磁共振色谱(NMR)使用Varian-400核磁共振仪测定；液质连用(LC/MS)使用Agilent Technologies 6120液质联用仪。
此外，凡涉及易氧化或易水解的原料的所有操作都在氮气保护下进行。除非另有说明，本发明使用的原料都是市售原料、无需进一步纯化可以直接使用。
PE：石油醚
EA：乙酸乙酯
DCM：二氯甲烷
CH3CN：乙腈
Sec-BuOH：仲丁醇
MeOH：甲醇
EtOH：乙醇
DMF：N,N’-二甲基甲酰胺
Et3N：三乙胺
DIPEA：N,N’-二异丙基乙胺
HOAc：乙酸
2M HCl in EA：2mol/L盐酸乙酸乙酯溶液
Na2CO3：碳酸钠
Cs2CO3：碳酸铯
Pd2(dba)3：三(二亚苄基丙酮)二钯
Pd(PPh3)4：四(三苯基膦)钯
RuPhos：2-二环己基磷-2’,6’-二异丙氧基-1,1’-联苯
TLC：薄层硅胶板(G254)分析
P-TLC：制备薄层硅胶板
实施例一2-氨基-8-(4-甲氧基苄基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
(2-Amino-8-(4-methoxybenzyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
步骤1：6-氯-N4-(4-甲氧基苄基)吡啶-2,4,5-三胺的合成
2,5-二氨基-4,6-二氯嘧啶(1.79g，10.0mmol，1.0equiv.)，4-甲氧基苄胺(2.06g，15.0mmol，1.5equiv.)，Et3N(2.02g，20.0mmol，2.0equiv.)溶于适量Sec-BuOH，氮气保护下，105℃搅拌12小时。TLC实时监测反应。反应毕，于2～8℃静置至析出固体，过滤，先后用冷乙醇、石油醚洗涤，干燥，即得到粉红色固体(2.0g，收率：71.5％)。
ESI(m/z):[M+1]+279.9；1H NMR(400MHz,DMSO-d6)δ7.25(d,J＝8.4Hz,2H),6.94(s,1H),6.87(d,J＝8.5Hz,2H),5.67(s,2H),4.47(s,2H),3.93(s,2H),3.71(s,3H).
步骤2：2-氨基-4-氯-8-(4-甲氧基苄基)喋啶-7(8H)-酮的合成
6-氯-N4-(4-甲氧基苄基)吡啶-2,4,5-三胺(1.0g，3.6mmol，1.0equiv.)溶于乙醇(15mL)，随后滴加乙醛酸乙酯的50wt.％甲苯溶液(795.5mg)、冰醋酸(1090.2μL)，密封，80℃搅拌4～6小时。TLC实时监测反应。反应毕，于2～8℃静置至析出固体，过滤，先后用冷乙醇、石油醚洗涤，干燥，即得到黄色固体(802.2mg，收率：70.6％)。
ESI(m/z):[M+1]+317.8；1H NMR(400MHz,DMSO-d6)δ7.89(s,1H),7.87(s,2H),7.35(d,J＝7.6Hz,2H),6.84(d,J＝7.5Hz,2H),5.24(s,2H),3.70(s,3H).
步骤3：2-氨基-8-(4-甲氧基苄基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮的合成
2-氨基-4-氯-8-(4-甲氧基苄基)喋啶-7(8H)-酮(158.9mg，0.5mmol，1.0equiv.)，5-甲基呋喃硼酸(125.9mg，1.0mmol，2.0equiv.)，Pd(PPh3)4(115.6mg，20％)，Na2CO3(105.9mg，1.0mmol，2.0equiv.)溶于dioxane/H2O(6mL/0.6mL)，氮气置换2min，密闭，95℃搅拌12小时。TLC实时监测反应。反应毕，冷至室温，用DCM/MeOH(10:1)稀释，依次用水、饱和食盐水洗涤，有机相浓缩后经硅胶柱层析(DCM/MeOH＝200/1)分离得到黄色固体(120.1mg，收率：66.1％)。
ESI(m/z):[M+1]+363.8；1H NMR(400MHz,DMSO-d6)δ7.88(s,1H),7.75(d,J＝3.0Hz,1H),7.51(brs,2H),7.38(d,J＝6.4Hz,2H),6.84(d,J＝6.5Hz,2H),6.38(d,J＝3.6Hz,1H),5.28(s,2H),3.69(s,3H),2.39(s,3H).
实施例二2-氨基-8-(3-甲氧基苄基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
(2-Amino-8-(3-methoxybenzyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例1。
ESI(m/z):[M+1]+363.8；1H NMR(400MHz,DMSO-d6)δ7.90(s,1H),7.77(d,J＝3.5Hz,1H),7.52(brs,2H),7.21(t,J＝7.9Hz,1H),6.97(s,1H),6.92(d,J＝7.5Hz,1H),6.82(d,J＝8.1Hz,1H),6.39(d,J＝3.6Hz,1H),5.34(s,2H),3.72(s,3H),2.41(s,3H).
实施例三2-氨基-8-(2-甲氧基苄基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
(2-Amino-8-(2-methoxybenzyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例1。
ESI(m/z):[M+1]+363.8；1H NMR(400MHz,DMSO-d6)δ7.93(s,1H),7.81(d,J＝3.4Hz,1H),7.56(brs,2H),7.21(d,J＝8.0Hz,1H),7.02(d,J＝8.2Hz,1H),6.78(t,J＝7.3Hz,1H),6.58(d,J＝7.6Hz,1H),6.41(s,1H),5.31(s,2H),3.87(s,3H),2.41(s,3H).
实施例四2-氨基-8-(3-氟苄基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
(2-Amino-8-(3-fluorobenzyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例1。
ESI(m/z):[M+1]+351.8；1H NMR(400MHz,DMSO-d6)δ7.90(s,1H),7.77(d,J＝3.3Hz,1H),7.54(brs,2H),7.35(dd,J＝14.3,7.9Hz,1H),7.22(t,J＝8.5Hz,2H),7.09(t,J＝8.5Hz,1H),6.39(d,J＝3.3Hz,1H),5.36(s,2H),2.40(s,3H).
实施例五2-氨基-4-(5-甲基呋喃-2-基)-8-(3-(三氟甲基)苄基)喋啶-7(8H)-酮
(2-Amino-4-(5-methylfuran-2-yl)-8-(3-(trifluoromethyl)benzyl)pteridin-7(8H)-one)
路线参照实施例1。
ESI(m/z):[M+1]+401.8；1H NMR(400MHz,DMSO-d6)δ7.91(s,1H),7.79–7.76(m,2H),7.67–7.61(m,2H),7.54–7.48(m,3H),6.40(d,J＝2.6Hz,1H),5.44(s,2H),2.40(s,3H).
实施例六3-((2-氨基-4-(5-甲基呋喃-2-基)-7-氧代喋啶-8(7H)-基)亚甲基)苯 腈
(3-((2-Amino-4-(5-methylfuran-2-yl)-7-oxopteridin-8(7H)-yl)methyl)benzonit rile)
路线参照实施例1。
ESI(m/z):[M+1]+358.8；1H NMR(400MHz,DMSO-d6)δ7.91(s,1H),7.87(s,1H),7.77(d,J＝3.3Hz,1H),7.75–7.70(m,2H),7.64–7.41(m,3H),6.39(dd,J＝3.4,0.9Hz,1H),5.38(s,2H),2.40(s,3H).
实施例七(S)-2-氨基-4-(5-甲基呋喃-2-基)-8-((6-(((四氢呋喃-3-基)氧基)甲 基)吡啶-2-基)亚甲基)喋啶-7(8H)-酮
((S)-2-Amino-4-(5-methylfuran-2-yl)-8-((6-(((tetrahydrofuran-3-yl)oxy)methyl)pyridin-2-yl)methyl)pteridin-7(8H)-one)
步骤1：(S)-2-氰基-6-(((四氢呋喃-3-基)氧)甲基)吡啶的合成
(S)-3-羟基四氢呋喃(440.6mg，5.0mmol，1.0equiv.)溶于适量无水DMF，0℃条件下缓缓加入NaH(60wt.％，240mg，6.0mmol，1.2equiv.)，氮气保护下搅拌10分钟后，缓慢滴加2-氰基-6-溴甲基吡啶(1083.7mg，5.5mmol，1.1equiv.)的无水DMF溶液，然后移至室温搅拌4～6小时。TLC实时监测反应。反应毕，冷至室温，用EA稀释，依次用清水、饱和食盐水洗涤，有机相浓缩后经硅胶柱层析(DCM/MeOH＝200/1)分离得到黄色油状液体(802.3mg，收率：78.6％)。
步骤2：(S)-2-胺甲基-6-((四氢呋喃-3-基)氧)甲基吡啶的合成
(S)-2-氰基-6-(((四氢呋喃-3-基)氧)甲基)吡啶(802.3mg，3.9mmol，1.0equiv.)溶于MeOH/EA(3mL/3mL)，氮气保护下加入10wt.％的钯碳(80.2mg)，氢气置换，室温搅拌8小时。TLC实时监测反应。反应毕，硅藻土过滤，有机相旋干得到黄色油状液体(781.7mg，直接用于下一步)。
步骤3：(S)-6-氯-N4-((6-(((四氢呋喃-3-基)氧)甲基)吡啶-2-基)甲基)嘧啶-2,4,5-三胺的合成
2,5-二氨基-4,6-二氯嘧啶(671.8mg，3.7mmol，1.0equiv.)，(S)-2-胺甲基-6-((四氢呋喃-3-基)氧)甲基吡啶(781.7mg，3.7mmol，1.0equiv.)，Et3N(5.6g，55.5mmol，15.0equiv.)溶于适量Sec-BuOH，氮气保护下，105℃搅拌24小时。反应液冷至室温，用EA稀释，依次用清水、饱和食盐水洗涤，有机相浓缩后经硅胶柱层析(DCM/MeOH/NH4OH＝200/3/0.5～200/5/0.5)分离得到黄色固体(736.7mg，收率：56.8％)。
步骤4：(S)-2-氨基-4-氯-8-((6-(((四氢呋喃-3-基)氧)甲基)吡啶-2-基)甲基)喋啶-7(8H)-酮的合成
(S)-6-氯-N4-((6-(((四氢呋喃-3-基)氧)甲基)吡啶-2-基)甲基)嘧啶-2,4,5-三胺(526.2mg，1.5mmol，1.0equiv.)溶于乙醇(8mL)，随后滴加乙醛酸乙酯的50wt.％甲苯溶液(333.3mg)、冰醋酸(456.8μL)，密封，80℃搅拌4～6小时。TLC实时监测反应。反应毕，于2～8℃静置至析出固体，过滤，先后用冷乙醇、石油醚洗涤，干燥，即得到黄色固体(120.7mg，收率：34.4％)。
步骤5：3-((2-氨基-4-(5-甲基呋喃-2-基)-7-氧代喋啶-8(7H)-基)亚甲基)苯腈的合成
(S)-2-氨基-4-氯-8-((6-(((四氢呋喃-3-基)氧)甲基)吡啶-2-基)甲基)喋啶-7(8H)-酮(97.2mg，0.25mmol，1.0equiv.)，5-甲基呋喃硼酸(62.9mg，0.5mmol，2.0equiv.)，Pd(PPh3)4(57.8mg，20％)，Na2CO3(53.0mg，0.5mmol，2.0equiv.)溶于dioxane/H2O(6mL/0.6mL)，氮气置换2min，密闭，95℃搅拌12小时。TLC实时监测反应。反应毕，冷至室温，用DCM/MeOH(10:1)稀释，依次用水、饱和食盐水洗涤，有机相浓缩后经硅胶柱层析(DCM/MeOH/NH4OH＝200/3/0.5～200/5/0.5)分离得到黄色固体(35.4mg，收率：32.6％)。
ESI(m/z):[M+1]+434.9；1H NMR(400MHz,DMSO-d6)δ7.94(s,1H),7.81(d,J＝3.4Hz,1H),7.71(t,J＝7.8Hz,1H),7.60(brs,2H),7.28(d,J＝7.7Hz,1H),7.08(d,J＝7.8Hz,1H),6.42(d,J＝3.4Hz,1H),5.46(s,2H),4.44(s,2H),3.76–3.59(m,5H),2.41(s,3H),1.91(t,J＝6.4Hz,2H).
实施例八2-氨基-4-(5-甲基呋喃-2-基)-8-(吡啶-2-基亚甲基)喋啶-7(8H)-酮
(2-Amino-4-(5-methylfuran-2-yl)-8-(pyridin-2-ylmethyl)pteridin-7(8H)-one)
路线参照实施例1。
ESI(m/z):[M+1]+334.8；1H NMR(400MHz,DMSO-d6)δ8.71(s,1H),8.46(s,1H),7.91–7.90(m,1H),7.82–7.80(m,1H),7.76–7.75(m,1H),7.60(brs,2H),7.33(d,J＝4.4Hz,1H),6.39(d,J＝3.3Hz,1H),5.36(s,2H),2.40(s,3H).
实施例九2-氨基-8-(呋喃-2-基亚甲基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
(2-Amino-8-(furan-2-ylmethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例1。
ESI(m/z):[M+1]+323.8；1H NMR(400MHz,DMSO-d6)δ7.88(s,1H),7.75(d,J＝3.4Hz,1H),7.55(brs,2H),6.42(d,J＝3.2Hz,1H),6.40–6.36(m,2H),5.75(s,1H),5.35(s,2H),2.40(s,3H).
实施例十2-氨基-8-(环己基亚甲基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
(2-Amino-8-(cyclohexylmethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例1。
ESI(m/z):[M+1]+339.8；1H NMR(400MHz,DMSO-d6)δ7.84(s,1H),7.75(s,1H),7.40(brs,2H),6.38(d,J＝3.6Hz,1H),4.04(d,J＝7.2Hz,2H),2.39(s,3H),1.92–1.82(m,1H),1.66–1.64(m,2H),1.66–1.55(m,4H),1.07–1.02(m,4H).
实施例十一2-氨基-8-(环丙基亚甲基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
(2-Amino-8-(cyclopropylmethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例1。
ESI(m/z):[M+1]+297.8；1H NMR(400MHz,DMSO-d6)δ7.87(s,1H),7.75(d,J＝2.7Hz,2H),7.52(brs,2H),6.39(d,J＝4.0Hz,2H),4.05(d,J＝7.0Hz,2H),2.40(s,3H),1.36–1.21(m,1H),0.44(dd,J＝5.4,2.5Hz,4H).
实施例十二2-氨基-8-苄基-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
(2-Amino-8-benzyl-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例1。
ESI(m/z):[M+1]+333.8；1H NMR(400MHz,DMSO-d6)δ7.90(s,1H),7.78–7.74(m,1H),7.66(s,2H),7.44–7.20(m,5H),6.39–6.37(m,1H),5.36(s,2H),2.39(s,3H).
实施例十三2-氨基-4-(5-甲基呋喃-2-基)-8-苯乙基喋啶-7(8H)-酮
(2-Amino-4-(5-methylfuran-2-yl)-8-phenethylpteridin-7(8H)-one)
路线参照实施例1。
ESI(m/z):[M+1]+347.8；1H NMR(400MHz,DMSO-d6)δ7.85(s,1H),7.75(d,J＝3.3Hz,1H),7.52(brs,2H),7.31(dd,J＝4.4,1.5Hz,4H),7.23(q,J＝4.2Hz,1H),6.39(d,J＝3.7Hz,1H),4.42–4.25(m,2H),2.94–2.90(m,2H),2.40(s,3H).
实施例十四2-氨基-4-(5-甲基呋喃-2-基)-8-(3-苯正丙基)喋啶-7(8H)-酮
(2-Amino-4-(5-methylfuran-2-yl)-8-(3-phenylpropyl)pteridin-7(8H)-one)
路线参照实施例1。
ESI(m/z):[M+1]+361.8；1H NMR(400MHz,DMSO-d6)δ7.83(s,1H),7.74(d,J＝3.4Hz,1H),7.45(s,2H),7.28–7.19(m,4H),7.17–7.11(m,1H),6.38(dd,J＝3.4,0.9Hz,1H),4.24–4.18(m,2H),2.72–2.59(m,2H),2.39(s,3H),1.97(dt,J＝15.2,7.7Hz,2H).
实施例十五2-氨基-4-(5-甲基呋喃-2-基)-8-(4-苯正丁基)喋啶-7(8H)-酮
(2-Amino-4-(5-methylfuran-2-yl)-8-(4-phenylbutyl)pteridin-7(8H)-one)
路线参照实施例1。
ESI(m/z):[M+1]+375.9；1H NMR(400MHz,DMSO-d6)δ7.83(s,1H),7.74(d,J＝3.3Hz,1H),7.45(brs,2H),7.28–7.22(m,2H),7.21–7.12(m,3H),6.38(dd,J＝3.4,0.9Hz,1H),4.19(t,J＝7.0Hz,2H),2.62(t,J＝7.5Hz,2H),2.39(s,3H),1.75–1.49(m,4H).
实施例十六2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(4-甲基哌嗪-1-基)乙基)喋啶- 7(8H)-酮
(2-Amino-4-(5-methylfuran-2-yl)-8-(2-(4-methylpiperazin-1-yl)ethyl)pteridin-7(8H)-one)
路线参照实施例1。
ESI(m/z):[M+1]+369.8；1H NMR(400MHz,DMSO-d6)δ7.84(s,1H),7.75(d,J＝3.3Hz,1H),7.46(brs,2H),6.38(d,J＝3.4Hz,1H),4.27(t,J＝6.9Hz,2H),2.55(t,J＝6.9Hz,2H),2.50(s,3H),2.39–2.23(m,8H),2.11(s,3H).
实施例十七2-氨基-8-(2-(4-环戊基哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)喋 啶-7(8H)-酮
(2-Amino-8-(2-(4-cyclopentylpiperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例1。
ESI(m/z):[M+1]+423.9；1H NMR(400MHz,DMSO-d6)δ7.84(s,1H),7.75(d,J＝3.3Hz,1H),7.45(brs,2H),6.38(d,J＝3.4Hz,1H),4.28(t,J＝6.9Hz,2H),2.55–2.25(m,9H),2.01–1.97(m,2H),1.76–1.72(m,1H),1.59–1.57(m,2H),1.49–1.46(m,4H),1.45–1.43(m,4H).
实施例十八2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(4-苯基哌嗪-1-基)乙基)喋啶- 7(8H)-酮
(2-Amino-4-(5-methylfuran-2-yl)-8-(2-(4-phenylpiperazin-1-yl)ethyl)pteridin-7(8H)-one)
步骤1：叔丁基(2-(4-苯基哌嗪-1-基)乙基)氨基甲酸酯的合成
苯基哌嗪(486.7mg，3.0mmol，1.0equiv.)和Boc-溴乙胺(806.8mg，3.6mmol，1.2equiv.)溶于适量乙腈(9mL)，随后滴加DIPEA(465.3mg，3.6mmol，1.2equiv.)，75℃搅拌4小时。TLC实时监测反应。反应毕，用DCM/MeOH(20/1)稀释，依次用水、饱和食盐水洗涤，有机相浓缩后得到粗品，直接用于下一步。
步骤2：6-氯-N4-(2-(4-苯基哌嗪-1-基)乙基)嘧啶-2,4,5-三胺的合成
上一步的叔丁基(2-(4-苯基哌嗪-1-基)乙基)氨基甲酸酯(1.33g，3.6mmol，2.4equiv.)溶于甲醇(5mL)，随后滴加4M的盐酸二氧六环溶液(4mL)，室温搅拌4小时。TLC实时监测反应。反应毕，冷却至室温，析出大量固体，过滤干燥得到白色固体，溶于适量异丙醇，边搅拌边缓慢滴加Et3N(1.5mL)，再加入2,5-二氨基-4,6-二氯嘧啶(268.0mg，1.5mmol，1.0equiv.)，氮气保护下，105℃搅拌16小时。TLC实时监测反应。反应毕，用DCM/MeOH(20/1)稀释，依次用水、饱和食盐水洗涤，有机相浓缩后经硅胶柱层析(DCM/MeOH/NH3·H2O＝200/5.0/0.5～200/8.0/0.5)分离得到类白色固体(381.2mg，收率：73.2％)。
步骤3：2-氨基-4-氯-8-(2-(4-苯基哌嗪-1-基)乙基)喋啶-7(8H)-酮的合成
6-氯-N4-(2-(4-苯基哌嗪-1-基)乙基)嘧啶-2,4,5-三胺(381.2mg，1.1mmol，1.0equiv.)溶于乙醇(4mL)，随后滴加乙醛酸乙酯的50wt.％甲苯溶液(244.4mg)、冰醋酸(336.3μL)，密封，80℃搅拌4～6小时。TLC实时监测反应。反应毕，用DCM/MeOH(20/1)稀释，依次用水、饱和食盐水洗涤，有机相浓缩后经硅胶柱层析(PE/EA＝3/1～2/3)分离得到黄色固体(61.3mg，收率：14.5％)。
步骤4：2-氨基-4-氯-8-(2-(4-环戊基哌嗪-1-基)乙基)喋啶-7(8H)-酮的合成
6-氯-N4-(2-(4-环戊基哌嗪-1-基)乙基)嘧啶-2,4,5-三胺(110.0mg，0.3mmol，1.0equiv.)，溶于乙醇(4mL)，随后滴加乙醛酸乙酯的50wt.％甲苯溶液(71.8mg)、冰醋酸(98.8μL)，密封，80℃搅拌4～6小时。TLC实时监测反应。反应毕，用DCM/MeOH(20/1)稀释，依次用水、饱和食盐水洗涤，有机相浓缩后经硅胶柱层析(DCM/MeOH/NH3·H2O＝200/2.5/0.5～200/7.5/0.5)分离得到白色固体(91.2mg，收率：74.5％)。
步骤5：2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(4-苯基哌嗪-1-基)乙基)喋啶-7(8H)-酮的合成
2-氨基-4-氯-8-(2-(4-环戊基哌嗪-1-基)乙基)喋啶-7(8H)-酮(60.0mg，0.15mmol，1.0equiv.)，5-甲基呋喃硼酸(37.8mg，0.3mmol，2.0equiv.)，Pd(PPh3)4(26.0mg，15％)，Na2CO3(31.8mg，0.3mmol，2.0equiv.)溶于dioxane/H2O(4mL/0.5mL)，氮气置换2min，密闭，95℃搅拌12小时。TLC实时监测反应。反应毕，用DCM/MeOH(20/1)稀释，依次用水、饱和食盐水洗涤，有机相浓缩后经硅胶柱层析(DCM/MeOH＝50/1～30/1)分离得到黄色固体(26.3mg，收率：39.2％)。
ESI(m/z):[M+1]+431.8；1H NMR(400MHz,DMSO-d6)δ7.86(s,1H),7.75(d,J＝3.3Hz,1H),7.44(brs,2H),7.19(t,J＝7.9Hz,2H),6.89(d,J＝8.1Hz,2H),6.76(t,J＝7.1Hz,1H),6.38(d,J＝2.5Hz,1H),4.34(t,J＝6.6Hz,2H),3.12–2.98(m,4H),2.72–2.54(m,6H),2.39(s,3H).
实施例十九2-氨基-8-(2-(4-(2-甲氧基苯基)哌嗪-1-基)乙基)-4-(5-甲基呋喃- 2-基)喋啶-7(8H)-酮
(2-Amino-8-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
步骤1：叔丁基4-(2-甲氧基苯基)哌嗪-1-氨基甲酸酯的合成
氮气保护下，2-甲氧基碘苯(1.17g，5.0mmol，1.0equiv.)，Boc-哌嗪(931.3mg，5.0mmol，1.0equiv.)，Cs2CO3(2.11g，6.5mmol，1.3equiv.)，Pd2(dba)3(45.7mg，1％)，RuPhos(69.9mg，3％)溶于适量甲苯，密封，105℃搅拌24小时。TLC实时监测反应。反应毕，用EA稀释，依次用水、饱和食盐水洗涤，有机相浓缩后经硅胶柱层析(PE/EA＝20/1～5/1)分离得到黄色粘稠油状物(1.07g，收率：73.2％)。
步骤2：叔丁基(2-(4-(2-甲氧基苯基)哌嗪-1-基)乙基)氨基甲酸酯的合成
上一步的叔丁基4-(2-甲氧基苯基)哌嗪-1-氨基甲酸酯(1.07g，3.66mmol，1.0equiv.)溶于甲醇(5mL)，随后滴加4M的盐酸二氧六环溶液(4mL)，室温搅拌4小时。TLC实时监测反应。反应毕，冷却至室温，析出大量固体，过滤干燥得到白色固体，直接用于下一步。溶于适量乙腈(7mL)，边搅拌边缓慢滴加Et3N(5mL)，再每12小时加入Boc-溴乙胺(820.2mg，3.66mmol，1.0equiv.)*2次，氮气保护下，75℃搅拌24小时。TLC实时监测反应。反应毕，用EA稀释，依次用水、饱和食盐水洗涤，有机相浓缩后经硅胶柱层析(DCM/MeOH＝200/3～200/6)分离得到黄色粘稠油状物(1.23g，收率：100.0％)。
步骤3：6-氯-N4-(2-(4-(2-甲氧基苯基)哌嗪-1-基)乙基)嘧啶-2,4,5-三胺的合成上一步的叔丁基(2-(4-(2-甲氧基苯基)哌嗪-1-基)乙基)氨基甲酸酯(1.23g，3.66mmol，1.0equiv.)溶于甲醇(5mL)，随后滴加4M的盐酸二氧六环溶液(4mL)，室温搅拌4小时。TLC实时监测反应。反应毕，冷却至室温，析出大量固体，过滤干燥得到白色固体，直接用于下一步。溶于适量Sec-BuOH，边搅拌边缓慢滴加Et3N(7mL)，再加入2,5-二氨基-4,6-二氯嘧啶(655.1mg，3.66mmol，1.0equiv.)，氮气保护下，105℃搅拌24小时。TLC实时监测反应。反应毕，用EA稀释，依次用水、饱和食盐水洗涤，有机相浓缩后经硅胶柱层析(DCM/MeOH/NH3·H2O＝200/3.0/0.5～200/6.0/0.5)分离得到淡黄色固体(604.4mg，收率：43.7％)。
步骤4：2-氨基-4-氯-8-(2-(4-(2-甲氧基苯基)哌嗪-1-基)乙基)喋啶-7(8H)-酮的合成
6-氯-N4-(2-(4-(2-甲氧基苯基)哌嗪-1-基)乙基)嘧啶-2,4,5-三胺(566.8mg，1.5mmol，1.0equiv.)溶于乙醇(4mL)，随后滴加乙醛酸乙酯的50wt.％甲苯溶液(333.3mg)、冰醋酸(456.8μL)，密封，80℃搅拌4～6小时。TLC实时监测反应。反应毕，冷却至室温，过滤分离得到黄色固体(510.3mg，收率：81.8％)。
步骤5：2-氨基-8-(2-(4-(2-甲氧基苯基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮的合成
2-氨基-4-氯-8-(2-(4-(2-甲氧基苯基)哌嗪-1-基)乙基)喋啶-7(8H)-酮(103.9mg，0.25mmol，1.0equiv.)，5-甲基呋喃硼酸(62.9mg，0.5mmol，2.0equiv.)，Pd(PPh3)4(43.4mg，15％)，Na2CO3(53.0mg，0.5mmol，2.0equiv.)溶于dioxane/H2O(5mL/0.5mL)，氮气置换2min，密闭，95℃搅拌12小时。TLC实时监测反应。反应毕，用DCM/MeOH(20/1)稀释，依次用水、饱和食盐水洗涤，有机相浓缩后经硅胶柱层析(DCM/MeOH/NH3·H2O＝200/3.0/0.5～200/5.0/0.5)分离得到淡黄色固体(93.9mg，收率：81.4％)。
ESI(m/z):[M+1]+461.8；1H NMR(400MHz,DMSO-d6)δδ7.86(s,1H),7.75(d,J＝3.4Hz,1H),7.44(brs,2H),6.93–6.90(m,2H),6.85–6.83(m,2H),6.41–6.30(m,1H),4.33(t,J＝6.7Hz,2H),3.76(s,3H),2.90(s,4H),2.63(s,6H),2.40(s,3H).
实施例二十2-氨基-8-(2-(4-(3-甲氧基苯基)哌嗪-1-基)乙基)-4-(5-甲基呋喃- 2-基)喋啶-7(8H)-酮
(2-Amino-8-(2-(4-(3-methoxyphenyl)piperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+461.8；1H NMR(400MHz,DMSO-d6)δ7.85(s,1H),7.74(d,J＝3.3Hz,1H),7.45(brs,2H),7.08(t,J＝8.2Hz,1H),6.48(dd,J＝8.2,1.9Hz,1H),6.42–6.30(m,3H),4.33(t,J＝6.7Hz,2H),3.70(s,3H),3.09–3.00(m,4H),2.65–2.50(m,6H),2.39(s,3H).
实施例二十一2-氨基-8-(2-(4-(4-甲氧基苯基)哌嗪-1-基)乙基)-4-(5-甲基呋 喃-2-基)喋啶-7(8H)-酮
(2-Amino-8-(2-(4-(4-methoxyphenyl)piperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+461.9；1H NMR(400MHz,DMSO-d6)δ7.85(s,1H),7.75(d,J＝3.3Hz,1H),7.43(brs,2H),6.83–6.78(m,4H),6.38(dd,J＝3.4,0.9Hz,1H),4.33(t,J＝6.7Hz,2H),3.67(s,3H),2.94(s,4H),2.63(s,6H),2.39(s,3H).
实施例二十二2-氨基-8-(2-(4-(2-氟苯基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2- 基)喋啶-7(8H)-酮
(2-Amino-8-(2-(4-(2-fluorophenyl)piperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+449.9；1H NMR(400MHz,DMSO-d6)δ7.86(s,1H),7.75(d,J＝3.3Hz,1H),7.43(brs,2H),7.14–7.03(m,2H),7.02–6.90(m,2H),6.38(dd,J＝3.4,0.9Hz,1H),4.33(t,J＝6.7Hz,2H),2.94(s,4H),2.65(s,6H),2.39(s,3H).
实施例二十三2-氨基-8-(2-(4-(3-氟苯基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2- 基)喋啶-7(8H)-酮
(2-Amino-8-(2-(4-(3-fluorophenyl)piperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+449.9；1H NMR(400MHz,DMSO-d6)δ7.86(s,1H),7.75(d,J＝3.3Hz,1H),7.4Z5(brs,2H),7.19(dd,J＝15.7,8.0Hz,1H),6.70(t,J＝12.0Hz,2H),6.52(t,J＝8.3Hz,1H),6.38(dd,J＝3.4,0.9Hz,1H),4.33(t,J＝6.6Hz,2H),3.18–3.03(m,4H),2.73–2.55(m,6H),2.39(s,3H).
实施例二十四2-氨基-8-(2-(4-(4-氟苯基)哌嗪-1-基)乙基)-4-(5-甲基呋喃-2- 基)喋啶-7(8H)-酮
(2-Amino-8-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+449.9；1H NMR(400MHz,DMSO-d6)δ7.86(s,1H),7.75(d,J＝3.3Hz,1H),7.45(s,1H),7.02(t,J＝8.9Hz,2H),6.94–6.86(m,2H),6.38(dd,J＝3.4,0.9Hz,1H),4.33(t,J＝6.7Hz,2H),3.00(s,4H),2.73–2.57(m,6H),2.39(s,3H).
实施例二十五2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(4-(2-(三氟甲基)苯基)哌 嗪-1-基)乙基)喋啶-7(8H)-酮
(2-Amino-4-(5-methylfuran-2-yl)-8-(2-(4-(2-(trifluoromethyl)phenyl)piperazin-1-yl)ethyl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+499.9；1H NMR(400MHz,DMSO-d6)δ7.86(s,1H),7.75(d,J＝3.4Hz,1H),7.62(dd,J＝13.6,7.7Hz,2H),7.49(d,J＝8.0Hz,1H),7.43(brs,2H),7.30(t,J＝7.6Hz,1H),6.38(dd,J＝3.3,0.8Hz,1H),4.32(t,J＝6.7Hz,2H),2.81(t,J＝4.4Hz,4H),2.68–2.60(m,4H),2.51–2.49(m,2H),2.40(s,3H).
实施例二十六2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(4-(3-(三氟甲基)苯基)哌 嗪-1-基)乙基)喋啶-7(8H)-酮
(2-Amino-4-(5-methylfuran-2-yl)-8-(2-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)ethyl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+499.9；1H NMR(400MHz,DMSO-d6)δ7.85(s,1H),7.74(d,J＝3.3Hz,1H),7.48(brs,2H),7.40(t,J＝8.0Hz,1H),7.18(d,J＝8.4Hz,1H),7.11(s,1H),7.04(d,J＝7.6Hz,1H),6.37(dd,J＝3.4,0.9Hz,1H),4.33(t,J＝6.6Hz,2H),3.15(s,4H),2.72–2.56(m,6H),2.39(s,3H).
实施例二十七2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(4-(4-(三氟甲基)苯基)哌 嗪-1-基)乙基)喋啶-7(8H)-酮
(2-Amino-4-(5-methylfuran-2-yl)-8-(2-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)ethyl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+499.9；1H NMR(400MHz,DMSO-d6)δ7.86(s,1H),7.75(d,J＝3.1Hz,1H),7.59(brs,1H),7.49(d,J＝8.4Hz,2H),7.02(d,J＝8.9Hz,2H),6.38(s,1H),4.34(t,J＝6.6Hz,2H),3.25–3.15(m,4H),2.70–2.55(m,6H),2.39(s,3H).
实施例二十八2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(4-(2-(三氟甲氧基)苯基)哌 嗪-1-基)乙基)喋啶-7(8H)-酮
(2-Amino-4-(5-methylfuran-2-yl)-8-(2-(4-(2-(trifluoromethoxy)phenyl)piperazin-1-yl)ethyl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+515.8；1H NMR(400MHz,DMSO-d6)δ7.86(s,1H),7.75(d,J＝3.3Hz,1H),7.47(brs,2H),7.32–7.21(m,2H),7.11–6.98(m,2H),6.38(dd,J＝3.4,0.9Hz,1H),4.33(t,J＝6.4Hz,2H),2.93(s,4H),2.64(s,6H),2.39(s,3H).
实施例二十九2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(4-(3-(三氟甲氧基)苯基)哌 嗪-1-基)乙基)喋啶-7(8H)-酮
(2-Amino-4-(5-methylfuran-2-yl)-8-(2-(4-(3-(trifluoromethoxy)phenyl)piperazin-1-yl)ethyl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+515.8；1H NMR(400MHz,DMSO-d6)δ7.85(s,1H),7.74(d,J＝3.3Hz,1H),7.46(brs,2H),7.28(t,J＝8.3Hz,1H),6.91(dd,J＝8.5,2.1Hz,1H),6.78(s,1H),6.68(d,J＝8.1Hz,1H),6.38(dd,J＝3.4,0.9Hz,1H),4.33(t,J＝6.7Hz,2H),3.15–3.07(m,4H),2.66–2.62(m,6H),2.39(s,3H).
实施例三十2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(4-(4-(三氟甲氧基)苯基)哌 嗪-1-基)乙基)喋啶-7(8H)-酮
(2-Amino-4-(5-methylfuran-2-yl)-8-(2-(4-(4-(trifluoromethoxy)phenyl)piperazin-1-yl)ethyl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+515.8；1H NMR(400MHz,DMSO-d6)δ7.86(s,1H),7.75(d,J＝3.3Hz,1H),7.52(brs,2H),7.17(d,J＝8.7Hz,2H),6.96(d,J＝9.2Hz,2H),6.40–6.34(m,1H),4.33(t,J＝6.6Hz,2H),3.15–3.00(m,4H),2.75–2.55(m,6H),2.39(s,3H).
实施例三十一(S)-2-氨基-8-(2-(4-(4-甲氧基苯基)-2-甲基哌嗪-1-基)乙基)- 4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
((S)-2-Amino-8-(2-(4-(4-methoxyphenyl)-2-methylpiperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+475.9；1H NMR(400MHz,DMSO-d6)δ7.85(s,1H),7.75(d,J＝3.3Hz,1H),7.38(brs,2H),6.82(dd,J＝21.7,9.2Hz,4H),6.40–6.35(m,1H),4.46–4.34(m,1H),4.28–4.16(m,1H),3.67(s,3H),3.29–3.17(m,2H),3.13–2.97(m,2H),2.66–2.52(m,4H),2.39(s,3H),2.31–2.20(m,1H),0.99(d,J＝6.0Hz,3H).
实施例三十二(R)-2-氨基-8-(2-(4-(4-甲氧基苯基)-2-甲基哌嗪-1-基)乙基)- 4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
((R)-2-Amino-8-(2-(4-(4-methoxyphenyl)-2-methylpiperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+475.9；1H NMR(400MHz,DMSO-d6)δ7.85(s,1H),7.75(d,J＝3.3Hz,1H),7.46(brs,2H),6.82(dd,J＝21.8,9.2Hz,4H),6.38(dd,J＝3.4,0.9Hz,1H),4.46–4.32(m,1H),4.29–4.13(m,1H),3.67(s,3H),3.28–3.17(m,2H),3.14–2.96(m,2H),2.67–2.51(m,4H),2.39(s,3H),2.31–2.18(m,1H),0.99(d,J＝6.1Hz,3H).
实施例三十三(S)-2-氨基-8-(2-(4-(4-甲氧基苯基)-3-甲基哌嗪-1-基)乙基)- 4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
((S)-2-Amino-8-(2-(4-(4-methoxyphenyl)-3-methylpiperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+475.9；1H NMR(400MHz,DMSO-d6)δ7.85(s,1H),7.74(d,J＝3.3Hz,1H),7.46(brs,2H),6.81(q,J＝9.3Hz,4H),6.38(dd,J＝3.4,0.9Hz,1H),4.39–4.28(m,2H),3.67(s,3H),3.60–3.49(m,1H),2.96–2.88(m,1H),2.85–2.74(m,2H),2.69(dt,J＝12.8,6.5Hz,1H),2.60–2.52(m,2H),2.39(s,3H),0.73(d,J＝6.3Hz,3H).
实施例三十四(R)-2-氨基-8-(2-(4-(4-甲氧基苯基)-3-甲基哌嗪-1-基)乙基)- 4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
((R)-2-Amino-8-(2-(4-(4-methoxyphenyl)-3-methylpiperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+475.9；1H NMR(400MHz,DMSO-d6)δ7.85(s,1H),7.74(d,J＝3.3Hz,1H),7.45(brs,2H),6.88–6.74(m,4H),6.38(dd,J＝3.4,0.9Hz,1H),4.40–4.26(m,2H),3.67(s,3H),3.60–3.50(m,1H),2.95–2.88(m,1H),2.85–2.75(m,2H),2.73–2.63(m,1H),2.61–2.52(m,4H),2.39(s,3H),0.73(d,J＝6.3Hz,3H).
实施例三十五2-氨基-8-(2-((2S,5R)-4-(4-甲氧基苯基)-2,5-二甲基哌嗪-1- 基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
(2-Amino-8-(2-((2S,5R)-4-(4-methoxyphenyl)-2,5-dimethylpiperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+489.9；1H NMR(400MHz,DMSO-d6)δ7.86(s,1H),7.76(d,J＝3.4Hz,1H),7.38(brs,2H),6.95(d,J＝8.9Hz,2H),6.82(d,J＝9.0Hz,2H),6.42–6.36(m,1H),4.47–4.34(m,1H),4.29–4.18(m,1H),3.69(s,3H),3.13–2.90(m,4H),2.85–2.77(m,1H),2.69–2.61(m,1H),2.57–2.51(m,1H),2.26(dd,J＝10.8,8.0Hz,1H),0.91(d,J＝6.2Hz,3H),0.78(d,J＝6.1Hz,3H).
实施例三十六2-氨基-8-(2-((1S,4S)-5-(4-甲氧基苯基)-2,5-二氮杂双环 [2.2.1]庚烷-2-基)一乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
(2-Amino-8-(2-((1S,4S)-5-(4-methoxyphenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+473.9；1H NMR(400MHz,DMSO-d6)δ7.80(s,1H),7.72(d,J＝3.2Hz,1H),7.48(brs,2H),6.75(d,J＝9.0Hz,2H),6.48(d,J＝9.0Hz,2H),6.37(dd,J＝3.4,0.9Hz,1H),4.27–4.07(m,3H),3.64(s,3H),3.57(s,1H),3.29(s,1H),2.97(d,J＝9.0Hz,1H),2.89(d,J＝8.1Hz,1H),2.71–2.56(m,3H),2.39(s,3H),1.74(s,2H).
实施例三十七2-氨基-8-(2-(3-(4-甲氧基苯基)-3,8-二氮杂双环[3.2.1]辛烷- 8-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
(2-Amino-8-(2-(3-(4-methoxyphenyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+487.8；1H NMR(400MHz,DMSO-d6)δ7.84(s,1H),7.73(d,J＝3.3Hz,1H),7.43(brs,2H),6.76(d,J＝9.2Hz,2H),6.70(d,J＝9.2Hz,2H),6.37(dd,J＝3.4,0.9Hz,1H),4.30(t,J＝6.7Hz,2H),3.65(s,3H),3.41(s,2H),3.21(d,J＝9.9Hz,2H),2.62–2.50(m,4H),2.39(s,3H),1.84(d,J＝7.0Hz,2H),1.64(d,J＝7.0Hz,2H).
实施例三十八2-氨基-8-(2-(4-(4-甲氧基苯基)-1,4-二氮杂环庚烷-1-基)乙 基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
(2-Amino-8-(2-(4-(4-methoxyphenyl)-1,4-diazepan-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+475.8；1H NMR(400MHz,DMSO-d6)δ7.83(s,1H),7.75(d,J＝3.3Hz,1H),7.36(brs,2H),6.74(d,J＝9.0Hz,2H),6.61(d,J＝9.0Hz,2H),6.41–6.36(m,1H),4.26(t,J＝6.6Hz,2H),3.63(s,3H),3.41–3.36(m,2H),3.36–3.34(m,2H),2.86–2.77(m,2H),2.76–2.68(m,2H),2.65–2.56(m,2H),2.40(s,3H),1.85–1.70(m,2H).
实施例三十九2-氨基-4-(5-甲基呋喃-2-基)-8-((1-苯基哌啶-4-基)亚甲基)喋 啶-7(8H)-酮
(2-Amino-4-(5-methylfuran-2-yl)-8-((1-phenylpiperidin-4-yl)methyl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+416.8；1H NMR(400MHz,DMSO-d6)δ7.86(s,1H),7.76(d,J＝3.3Hz,1H),7.42(brs,2H),7.17(dd,J＝8.6,7.3Hz,2H),6.90(d,J＝8.0Hz,2H),6.72(t,J＝7.2Hz,1H),6.38(dd,J＝3.4,0.9Hz,1H),4.13(d,J＝7.2Hz,2H),3.67(d,J＝12.5Hz,2H),2.58(t,J＝11.2Hz,2H),2.40(s,3H),2.06(ddd,J＝11.3,7.5,3.8Hz,1H),1.64(d,J＝11.1Hz,2H),1.40(qd,J＝12.5,3.7Hz,2H).
实施例四十2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(1-苯基哌啶-4-基)乙基)喋啶- 7(8H)-酮
(2-Amino-4-(5-methylfuran-2-yl)-8-(2-(1-phenylpiperidin-4-yl)ethyl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+430.8；1H NMR(400MHz,DMSO-d6)δ7.84(s,1H),7.75(d,J＝3.3Hz,1H),7.37(brs,2H),7.18(dd,J＝8.6,7.3Hz,2H),6.91(d,J＝8.0Hz,2H),6.72(t,J＝7.2Hz,1H),6.38(dd,J＝3.4,0.9Hz,1H),4.26–4.16(m,2H),3.66(d,J＝12.4Hz,2H),2.62(dd,J＝11.9,10.3Hz,2H),2.39(s,3H),1.86(d,J＝11.1Hz,2H),1.60(dd,J＝14.5,6.9Hz,2H),1.48–1.38(m,1H),1.29(ddd,J＝15.3,12.3,3.7Hz,2H).
实施例四十一2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(4-苯基哌啶-1-基)乙基)喋 啶-7(8H)-酮
(2-Amino-4-(5-methylfuran-2-yl)-8-(2-(4-phenylpiperidin-1-yl)ethyl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+430.8；1H NMR(400MHz,DMSO-d6)δ7.86(s,1H),7.76(s,1H),7.40(brs,2H),7.32–7.11(m,5H),6.39(s,1H),5.78–5.71(m,1H),4.32(s,2H),3.09(d,J＝9.4Hz,2H),2.61(s,2H),2.40(s,3H),2.10(t,J＝10.9Hz,2H),1.72(d,J＝11.0Hz,2H),1.57–1.54(m,2H).
实施例四十二2-氨基-8-(2-(3-((4-甲氧基苯基)(甲基)氨基)吡咯-1-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
(2-Amino-8-(2-(3-((4-methoxyphenyl)(methyl)Amino)pyrrolidin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
步骤1：叔丁基3-((4-甲氧基苯基)(甲基)氨基)吡咯啉-1-氨基甲酸酯的合成氮气保护下，4-甲氧基碘苯(1.64g，7.0mmol，1.0equiv.)，叔丁基3-(甲胺基)吡咯啉-1-胺基甲酸酯(1.40g，7.0mmol，1.0equiv.)，Cs2CO3(2.73g，8.4mmol，1.2equiv.)，Pd2(dba)3(64.1mg，1％)，RuPhos(97.8mg，3％)溶于适量甲苯，密封，105℃搅拌24小时。TLC实时监测反应。反应毕，用EA稀释，依次用水、饱和食盐水洗涤，有机相浓缩后经硅胶柱层析(PE/EA＝20/1～5/1)分离得到黄棕色粘稠油状物(1860.0mg，收率：85.3％)。
步骤2：叔丁基(2-(3-((4-甲氧基苯基)(甲基)胺基)吡咯啉-1-基)乙基)胺基甲酸酯的合成
上一步的叔丁基3-((4-甲氧基苯基)(甲基)氨基)吡咯啉-1-氨基甲酸酯(1860.0mg，6.07mmol，1.0equiv.)溶于甲醇(8mL)，随后滴加4M的盐酸二氧六环溶液(6mL)，室温搅拌4小时。TLC实时监测反应。反应毕，冷却至室温，析出大量固体，过滤干燥得到白色固体，直接用于下一步。溶于适量乙腈(15mL)，边搅拌边缓慢滴加Et3N(8mL)，再每12小时加入Boc-溴乙胺(1086.6mg，6.07mmol，1.0equiv.)*2次，氮气保护下，75℃搅拌24小时。TLC实时监测反应。反应毕，用DCM/MeOH(20/1)稀释，依次用水、饱和食盐水洗涤，有机相浓缩后经硅胶柱层析(DCM/MeOH/NH3·H2O＝200/3.0/0.5～200/4.5/0.5)分离得到棕色油状物(855.0mg，收率：41.7％)。
步骤3：6-氯-N4-(2-(3-((4-甲氧基苯基)(甲基)胺基)吡咯啉-1-基)乙基)嘧啶-2,4,5-三胺的合成
上一步的叔丁基(2-(3-((4-甲氧基苯基)(甲基)胺基)吡咯啉-1-基)乙基)胺基甲酸酯(885.0mg，2.53mmol，1.0equiv.)溶于甲醇(6mL)，随后滴加4M的盐酸二氧六环溶液(4mL)，室温搅拌4小时。TLC实时监测反应。反应毕，冷却至室温，析出大量固体，过滤干燥得到白色固体，直接用于下一步。溶于适量Sec-BuOH，边搅拌边缓慢滴加Et3N(7mL)，再加入2,5-二氨基-4,6-二氯嘧啶(453.3mg，2.53mmol，1.0equiv.)，氮气保护下，105℃搅拌24小时。TLC实时监测反应。反应毕，用DCM/MeOH(20/1)稀释，依次用水、饱和食盐水洗涤，有机相浓缩后经硅胶柱层析(DCM/MeOH/NH3·H2O＝200/3.0/0.5～200/6.0/0.5)分离得到黄色固体(602.0mg，收率：60.6％)。
步骤4：2-胺基-4-氯-8-(2-(3-((4-甲氧基苯基)(甲基)胺基)吡咯啉-1-基)乙基)喋啶-7(8H)-酮的合成
6-氯-N4-(2-(3-((4-甲氧基苯基)(甲基)胺基)吡咯啉-1-基)乙基)嘧啶-2,4,5-三胺(587.8mg，1.5mmol，1.0equiv.)溶于乙醇(8mL)，随后滴加乙醛酸乙酯的50wt.％甲苯溶液(333.3mg)、冰醋酸(456.8μL)，密封，80℃搅拌4～6小时。TLC实时监测反应。反应毕，冷却至室温，过滤分离得到黄色固体(130.0mg，收率：20.1％)。
步骤5：2-氨基-8-(2-(3-((4-甲氧基苯基)(甲基)氨基)吡咯啉-1-基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮的合成
2-胺基-4-氯-8-(2-(3-((4-甲氧基苯基)(甲基)胺基)吡咯啉-1-基)乙基)喋啶-7(8H)-酮(107.5mg，0.25mmol，1.0equiv.)，5-甲基呋喃硼酸(62.9mg，0.5mmol，2.0equiv.)，Pd(PPh3)4(43.4mg，15％)，Na2CO3(53.0mg，0.5mmol，2.0equiv.)溶于dioxane/H2O(5mL/0.5mL)，氮气置换2min，密闭，95℃搅拌12小时。TLC实时监测反应。反应毕，用DCM/MeOH(20/1)稀释，依次用水、饱和食盐水洗涤，有机相浓缩后经硅胶柱层析(DCM/MeOH/NH3·H2O＝200/3.0/0.5～200/5.0/0.5)分离得到黄色固体(61.0mg，收率：51.3％)。
ESI(m/z):[M+1]+475.8；1H NMR(400MHz,DMSO-d6)δ7.85(s,1H),7.75(d,J＝3.3Hz,1H),7.43(brs,2H),6.75(s,4H),6.38(dd,J＝3.4,0.9Hz,1H),4.39–4.16(m,3H),3.65(s,3H),2.84–2.74(m,3H),2.63–2.53(m,5H),2.40(s,3H),2.39–2.30(m,1H),1.96(ddd,J＝16.7,12.9,4.1Hz,1H),1.58(td,J＝13.6,7.9Hz,1H).
实施例四十三2-氨基-8-(2-((1-(4-甲氧基苯基)吡咯-3-基)(甲基)氨基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
(2-Amino-8-(2-((1-(4-methoxyphenyl)pyrrolidin-3-yl)(methyl)Amino)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例42。
ESI(m/z):[M+1]+475.8；1H NMR(400MHz,DMSO-d6)δ7.84(s,1H),7.74(d,J＝3.3Hz,1H),7.45(brs,2H),6.75(d,J＝9.0Hz,2H),6.42(d,J＝9.0Hz,2H),6.38(dd,J＝3.4,0.8Hz,1H),4.37–4.24(m,2H),3.63(s,3H),3.29–3.16(m,3H),3.10(dd,J＝16.1,9.0Hz,1H),2.84(t,J＝7.7Hz,1H),2.74–2.73(m,2H),2.40(s,3H),2.35(s,3H),2.15–2.03(m,1H),1.69(dq,J＝17.8,8.9Hz,1H).
实施例四十四2-氨基-8-(2-(3-((4-甲氧基苯基)(甲基)氨基)氮杂环丁烷-1-基) 乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
(2-Amino-8-(2-(3-((4-methoxyphenyl)(methyl)Amino)azetidin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例42。
ESI(m/z):[M+1]+461.8；1H NMR(400MHz,DMSO-d6)δ7.85(s,1H),7.75(d,J＝3.3Hz,1H),7.46(brs,2H),6.79(d,J＝9.1Hz,2H),6.70(d,J＝9.1Hz,2H),6.38(dd,J＝3.4,0.9Hz,1H),4.16(t,J＝6.2Hz,2H),3.80(s,1H),3.66(s,5H),2.95(s,2H),2.73(s,2H),2.65(s,3H),2.40(s,3H).
实施例四十五2-氨基-8-(2-(4-(2-氟-4-甲氧基苯基)哌嗪-1-基)乙基)-4-(5-甲 基呋喃-2-基)喋啶-7(8H)-酮
(2-Amino-8-(2-(3-((4-methoxyphenyl)(methyl)amino)azetidin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+480.2；1H NMR(400MHz,DMSO-d6)δ7.85(s,1H),7.75(d,J＝3.4Hz,1H),7.42(s,2H),6.97–6.89(m,1H),6.77(dd,J＝14.1,2.8Hz,1H),6.67(dd,J＝8.8,2.3Hz,1H),6.38(dd,J＝3.3,1.1Hz,1H),4.33(t,J＝6.7Hz,2H),3.70(s,3H),2.85(s,4H),2.64(d,J＝6.5Hz,6H),2.40(s,3H).
实施例四十六2-氨基-8-(2-(4-(2,4-二氟苯基)哌嗪-1-基)乙基)-4-(5-甲基呋 喃-2-基)喋啶-7(8H)-酮
(2-Amino-8-(2-(3-((4-methoxyphenyl)(methyl)amino)azetidin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+462.2；1H NMR(400MHz,DMSO-d6)δ7.86(s,1H),7.75(d,J＝3.4Hz,1H),7.41(s,2H),7.15(ddd,J＝12.2,9.0,2.8Hz,1H),7.05–6.92(m,2H),6.38(dd,J＝3.4,1.1Hz,1H),4.33(t,J＝6.7Hz,2H),2.90(s,4H),2.65(s,6H),2.40(s,3H).
实施例四十七2-氨基-8-(2-(4-(2-氟-4-甲氧基苯基)哌嗪-1-基)乙基)-6-甲基- 4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
(2-Amino-8-(2-(4-(2-fluoro-4-methoxyphenyl)piperazin-1-yl)ethyl)-6-methyl-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
步骤1：2-氨基-4-氯-8-(2-(4-(2-氟-4-甲氧基苯基)哌嗪-1-基)乙基)-6-甲基喋啶-7(8H)-酮的合成
6-氯-N4-(2-(4-(2-氟-4-甲氧基苯基)哌嗪-1-基)乙基)嘧啶-2,4,5-三胺(170.2mg，0.43mmol，1.0equiv.)溶于乙醇(4mL)，随后滴加丙酮酸乙酯(54.9mg)、冰醋酸(130.9μL)，密封，80℃搅拌4～6小时。TLC实时监测反应。反应毕，冷却至室温，过滤分离得到棕褐色固体(139.2mg，收率：72.3％)。
步骤2：2-氨基-8-(2-(4-(2-氟-4-甲氧基苯基)哌嗪-1-基)乙基)-6-甲基-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮的合成
2-氨基-4-氯-8-(2-(4-(2-氟-4-甲氧基苯基)哌嗪-1-基)乙基)-6-甲基喋啶-7(8H)-酮(111.9mg，0.25mmol，1.0equiv.)，5-甲基呋喃硼酸(62.9mg，0.5mmol，2.0equiv.)，Pd(PPh3)4(43.4mg，15％)，Na2CO3(53.0mg，0.5mmol，2.0equiv.)溶于dioxane/H2O(5mL/0.5mL)，氮气置换2min，密闭，95℃搅拌12小时。TLC实时监测反应。反应毕，用DCM/MeOH(20/1)稀释，依次用水、饱和食盐水洗涤，有机相浓缩后经硅胶柱层析(DCM/MeOH/NH3·H2O＝200/3.0/0.5～200/5.0/0.5)分离得到黄色固体(75.8mg，收率：63.2％)。
ESI(m/z):[M+1]+493.9；1H NMR(400MHz,DMSO-d6)δ7.87(d,J＝3.2Hz,1H),7.24(brs,2H),6.98–6.89(m,1H),6.78(dd,J＝14.1,2.8Hz,1H),6.67(dd,J＝8.8,2.3Hz,1H),6.38(dd,J＝3.3,0.9Hz,1H),4.34(t,J＝6.8Hz,2H),3.70(s,3H),2.92–2.79(m,4H),2.74–2.54(m,6H),2.40(s,3H),2.39(s,3H).
实施例四十八2-氨基-8-(2-(4-(2-氟苯基)哌嗪-1-基)乙基)-6-甲基-4-(5-甲基 呋喃-2-基)喋啶-7(8H)-酮
(2-Amino-8-(2-(4-(2-fluorophenyl)piperazin-1-yl)ethyl)-6-methyl-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例47。
ESI(m/z):[M+1]+463.9；1H NMR(400MHz,DMSO-d6)δ7.86(d,J＝3.3Hz,1H),7.24(brs,2H),7.14–7.04(m,2H),7.00–6.92(m,2H),6.38(dd,J＝3.3,0.9Hz,1H),4.34(t,J＝6.7Hz,2H),2.95(s,4H),2.70–2.59(m,6H),2.40(s,3H),2.39(s,3H).
实施例四十九2-氨基-8-(2-(4-(2-氟苯基)哌嗪-1-基)乙基)-6-三氟甲基-4-(5- 甲基呋喃-2-基)喋啶-7(8H)-酮
(2-Amino-8-(2-(4-(2-fluorophenyl)piperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)-6-(trifluoromethyl)pteridin-7(8H)-one)
步骤1：2-氨基-4-氯-8-(2-(4-(2-氟苯基)哌嗪-1-基)乙基)-6-三氟甲基喋啶-7(8H)-酮的合成
6-氯-N4-(2-(4-(2-氟苯基)哌嗪-1-基)乙基)嘧啶-2,4,5-三胺(157.3mg，0.43mmol，1.0equiv.)溶于乙醇(4mL)，随后滴加三氟丙酮酸乙酯(80.5mg)、冰醋酸(130.9μL)，密封，80℃搅拌4～6小时。TLC实时监测反应。反应毕，冷却至室温，过滤分离得到棕褐色固体(110.8mg，收率：54.6％)。
步骤5：2-氨基-8-(2-(4-(2-氟苯基)哌嗪-1-基)乙基)-6-三氟甲基-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮的合成
2-氨基-4-氯-8-(2-(4-(2-氟苯基)哌嗪-1-基)乙基)-6-三氟甲基喋啶-7(8H)-酮(110.8mg，0.23mmol，1.0equiv.)，5-甲基呋喃硼酸(62.9mg，0.5mmol，2.0equiv.)，Pd(PPh3)4(43.4mg，15％)，Na2CO3(53.0mg，0.5mmol，2.0equiv.)溶于dioxane/H2O(5mL/0.5mL)，氮气置换2min，密闭，95℃搅拌12小时。TLC实时监测反应。反应毕，用DCM/MeOH(20/1)稀释，依次用水、饱和食盐水洗涤，有机相浓缩后经硅胶柱层析(DCM/MeOH/NH3·H2O＝200/3.0/0.5～200/5.0/0.5)分离得到黄色固体(55.8mg，收率：46.9％)。
ESI(m/z):[M+1]+517.9；1H NMR(400MHz,DMSO-d6)δ8.07(brs,NH,1H),7.78(brs,NH,1H),7.78(d,J＝3.4Hz,1H),7.14–7.04(m,2H),7.00–6.91(m,2H),6.45(dd,J＝3.4,0.9Hz,1H),4.35(t,J＝6.8Hz,2H),2.95(s,4H),2.66(s,6H),2.41(s,3H).
实施例五十2-(2-氨基-8-(2-(4-(2-氟苯基)哌嗪-1-基)乙基)-7-氧代-7,8-二氢 喋啶-4-基)-6-甲基苯甲腈
(2-(2-Amino-8-(2-(4-(2-fluorophenyl)piperazin-1-yl)ethyl)-7-oxo-7,8-dihydropteridin-4-yl)-6-methylbenzonitrile)
路线参照实施例19。
ESI(m/z):[M+1]+484.9；1H NMR(400MHz,DMSO-d6)δ7.90(dd,J＝7.7,1.2Hz,1H),7.77(s,1H),7.63(dd,J＝7.7,1.1Hz,1H),7.58(brs,2H),7.49(t,J＝7.7Hz,1H),7.15–7.06(m,2H),7.03–6.92(m,2H),4.35(t,J＝6.8Hz,2H),2.97(s,4H),2.68(s,6H),2.29(s,3H).
实施例五十一2-氨基-8-(2-(4-(2-氟苯基)哌嗪-1-基)乙基)-4-(1H-吡唑-4-基) 喋啶-7(8H)-酮
(2-Amino-8-(2-(4-(2-fluorophenyl)piperazin-1-yl)ethyl)-4-(1H-pyrazol-4-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+435.9；1H NMR(400MHz,DMSO-d6)δ13.31(s,1H),8.47(brs,2H),7.87(s,1H),7.26(s,2H),7.09(ddd,J＝15.7,7.8,1.4Hz,2H),7.01–6.91(m,2H),4.34(t,J＝6.6Hz,2H),2.94(s,4H),2.66(d,J＝5.1Hz,6H),1.99(s,3H).
实施例五十二2-氨基-8-(2-(4-(2-氟-4-(2-甲氧基乙氧基)苯基)哌嗪-1-基)乙 基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
(2-Amino-8-(2-(4-(2-fluoro-4-(2-methoxyethoxy)phenyl)piperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+523.8；1H NMR(400MHz,DMSO-d6)δ7.86(s,1H),7.75(d,J＝3.4Hz,1H),7.41(s,2H),6.92(t,J＝9.5Hz,1H),6.79(dd,J＝14.1,2.8Hz,1H),6.68(dd,J＝9.0,2.9Hz,1H),6.38(d,J＝2.8Hz,1H),4.33(t,J＝6.8Hz,2H),4.05–4.01(m,2H),3.64–3.60(m,2H),2.85(s,4H),2.65(s,6H),2.40(s,3H).
实施例五十三2-氨基-8-(2-(4-(2,3-二氟-4-(2-甲氧基乙氧基)苯基)哌嗪-1- 基)乙基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
(2-Amino-8-(2-(4-(2,3-difluoro-4-(2-methoxyethoxy)phenyl)piperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+541.8；1H NMR(400MHz,DMSO-d6)δ7.85(s,1H),7.75(d,J＝3.4Hz,1H),7.43(s,2H),6.88(td,J＝9.0,2.1Hz,1H),6.72(td,J＝9.2,2.3Hz,1H),6.38(dd,J＝3.4,1.1Hz,1H),4.32(t,J＝6.7Hz,2H),4.15–4.09(m,2H),3.68–3.61(m,2H),2.89(s,4H),2.65(s,6H),2.40(s,3H).
实施例五十四(S)-2-氨基-8-(2-(4-(2-氟-4-甲氧基苯基)-2-甲基哌嗪-1-基)乙 基)-4-(5-甲基呋喃-2-基)喋啶-7(8H)-酮
((S)-2-Amino-8-(2-(4-(2-fluoro-4-methoxyphenyl)-2-methylpiperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+493.8；1H NMR(400MHz,DMSO-d6)δ7.85(s,1H),7.75(d,J＝3.3Hz,1H),7.40(s,2H),6.91(t,J＝9.5Hz,1H),6.77(dd,J＝14.1,2.8Hz,1H),6.66(dd,J＝8.8,2.6Hz,1H),6.38(dd,J＝3.3,1.1Hz,1H),4.40(dt,J＝12.2,7.6Hz,1H),4.22(ddd,J＝12.4,8.3,4.4Hz,1H),3.70(s,3H),3.12–2.91(m,4H),2.71–2.52(m,4H),2.40(s,3H),2.35(dd,J＝11.0,8.5Hz,1H),0.98(d,J＝6.1Hz,3H).
实施例五十五2-氨基-8-(2-(4-(6-甲氧基吡啶-3-基)哌嗪-1-基)乙基)-6-甲基- 4-(5-甲基呋喃-2-基)蝶呤-7(8H)-酮
(2-Amino-8-(2-(4-(6-methoxypyridin-3-yl)piperazin-1-yl)ethyl)-6-methyl-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例47。
ESI(m/z):[M+1]+476.8；1H NMR(400MHz,DMSO-d6)δ7.85(d,J＝3.4Hz,1H),7.74(d,J＝3.0Hz,1H),7.40(dd,J＝9.0,3.1Hz,1H),7.24(s,2H),6.69(d,J＝9.0Hz,1H),6.38(dd,J＝3.3,1.1Hz,1H),4.34(t,J＝6.8Hz,2H),3.77(s,3H),3.11–2.92(m,4H),2.64(s,6H),2.39(s,6H).
实施例五十六2-氨基-8-(2-(4-(6-甲氧基吡啶-3-基)哌嗪-1-基)乙基)-4-(5-甲 基呋喃-2-基)蝶呤-7(8H)-酮
(2-Amino-8-(2-(4-(6-methoxypyridin-3-yl)piperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+462.8；1H NMR(400MHz,DMSO-d6)δ7.85(s,1H),7.74(t,J＝3.5Hz,2H),7.55–7.29(m,3H),6.69(d,J＝9.0Hz,1H),6.38(dd,J＝3.4,1.1Hz,1H),4.33(t,J＝6.7Hz,2H),3.77(s,3H),2.98(s,4H),2.65(s,6H),2.40(s,3H).
实施例五十七2-氨基-8-(2-(4-(5-甲氧基吡啶-2-基)哌嗪-1-基)乙基)-4-(5-甲 基呋喃-2-基)蝶呤-7(8H)-酮
(2-Amino-8-(2-(4-(5-methoxypyridin-2-yl)piperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+462.8；1H NMR(400MHz,DMSO-d6)δ7.87(d,J＝3.1Hz,1H),7.85(s,1H),7.74(d,J＝3.3Hz,1H),7.43(s,2H),7.24(dd,J＝9.1,3.1Hz,1H),6.76(d,J＝9.1Hz,1H),6.37(dd,J＝3.4,1.1Hz,1H),4.34(t,J＝6.7Hz,2H),3.72(s,3H),3.28(t,J＝5.1Hz,4H),2.63(t,J＝6.8Hz,2H),2.59(t,J＝5.0Hz,4H),2.40(s,3H).
实施例五十八2-氨基-8-(2-(4-(6-异丙氧基吡啶-3-基)哌嗪-1-基)乙基)-4-(5- 甲基呋喃-2-基)吡啶-7(8H)-酮
(2-Amino-8-(2-(4-(6-isopropoxypyridin-3-yl)piperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+490.8；1H NMR(400MHz,DMSO-d6)δ7.86(s,1H),7.73(dd,J＝11.4,3.2Hz,2H),7.37(dd,J＝9.0,3.1Hz,3H),6.61(d,J＝8.9Hz,1H),6.38(dd,J＝3.3,1.1Hz,1H),5.10(p,J＝6.1Hz,1H),4.33(t,J＝6.8Hz,2H),2.97(t,J＝4.8Hz,4H),2.64(s,6H),2.40(s,3H),1.24(d,J＝6.1Hz,6H).
实施例五十九2-氨基-8-(2-(4-(4-(二氟甲氧基)苯基)哌嗪-1-基)乙基)-4-(5- 甲基呋喃-2-基)蝶呤-7(8H)-酮
(2-Amino-8-(2-(4-(4-(difluoromethoxy)phenyl)piperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+497.8；1H NMR(400MHz,DMSO-d6)δ7.85(s,1H),7.75(d,J＝3.3Hz,1H),7.43(s,2H),7.22–6.83(m,5H),6.38(dd,J＝3.3,1.1Hz,1H),4.34(t,J＝6.8Hz,2H),3.04(s,4H),2.64(s,6H),2.39(s,3H).
实施例六十2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(4-(嘧啶-5-基)哌嗪-1-基)乙 基)蝶呤-7(8H)-酮
(2-Amino-4-(5-methylfuran-2-yl)-8-(2-(4-(pyrimidin-5-yl)piperazin-1-yl)ethyl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+433.8；1H NMR(400MHz,DMSO-d6)δ8.57(s,1H),8.44(s,2H),7.85(s,1H),7.74(d,J＝3.4Hz,1H),7.42(s,2H),6.38(dd,J＝3.3,1.1Hz,1H),4.34(t,J＝6.8Hz,2H),3.20(s,4H),2.65(s,6H),2.40(s,3H).
实施例六十一2-氨基-8-(2-(4-(3-氟-5-甲氧基吡啶-2-基)哌嗪-1-基)乙基)-4- (5-甲基呋喃-2-基)蝶呤-7(8H)-酮
(2-Amino-8-(2-(4-(3-fluoro-5-methoxypyridin-2-yl)piperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+480.8；1H NMR(400MHz,DMSO-d6)δ7.85(s,1H),7.79(d,J＝2.1Hz,1H),7.75(d,J＝3.3Hz,1H),7.33(dd,J＝14.0,2.6Hz,3H),6.38(dd,J＝3.4,1.1Hz,1H),4.33(t,J＝6.7Hz,2H),3.77(s,3H),3.14(s,4H),2.64(s,6H),2.40(s,3H).
实施例六十二2-氨基-8-(2-(4-(5-(二氟甲氧基)-3-氟吡啶-2-基)哌嗪-1-基)乙 基)-4-(5-甲基呋喃-2-基)蝶呤-7(8H)-酮
(2-Amino-8-(2-(4-(5-(difluoromethoxy)-3-fluoropyridin-2-yl)piperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+516.8；1H NMR(400MHz,DMSO-d6)δ7.98(d,J＝2.3Hz,
1H),7.85(s,1H),7.75(d,J＝3.4Hz,1H),7.61(dd,J＝13.3,2.4Hz,1H),7.54-6.95(m,3H),6.41–6.36(m,1H),4.33(t,J＝6.7Hz,2H),3.29(s,4H),2.64(s,6H),2.40(s,3H).
实施例六十三2-氨基-8-(2-(4-(5-(二氟甲氧基)-3-氟吡啶-2-基)哌嗪-1-基)乙 基)-6-甲基-4-(5-甲基呋喃-2-基)蝶呤-7(8H)-酮
(2-Amino-8-(2-(4-(5-(difluoromethoxy)-3-fluoropyridin-2-yl)piperazin-1-yl)ethyl)-6-methyl-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例47。
ESI(m/z):[M+1]+530.8；1H NMR(400MHz,DMSO-d6)δ7.97(d,J＝2.4Hz,1H),7.86(d,J＝3.3Hz,1H),7.60(dd,J＝13.3,2.4Hz,1H),7.34–6.94(m,3H),6.38(dd,J＝3.3,1.1Hz,1H),4.35(t,J＝6.8Hz,2H),3.30(s,4H),2.63(s,6H),2.40(s,6H).
实施例六十四2-氨基-8-(2-(4-(2-氟-4-(三氟甲氧基)苯基)哌嗪-1-基)乙基)- 4-(5-甲基呋喃-2-基)蝶呤-7(8H)-酮
(2-Amino-8-(2-(4-(2-fluoro-4-(trifluoromethoxy)phenyl)piperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+533.8；1H NMR(400MHz,DMSO-d6)δ7.86(s,1H),7.75(d,J＝3.3Hz,1H),7.41(s,2H),7.28(dd,J＝12.6,2.6Hz,1H),7.15–7.02(m,2H),6.38(dd,J＝3.4,1.1Hz,1H),4.33(t,J＝6.7Hz,2H),2.97(t,J＝4.6Hz,4H),2.66(s,6H),2.40(s,3H).
实施例六十五2-氨基-8-(2-(4-(2-氟-4-(三氟甲基)苯基)哌嗪-1-基)乙基)-4- (5-甲基呋喃-2-基)蝶呤-7(8H)-酮
(2-Amino-8-(2-(4-(2-fluoro-4-(trifluoromethyl)phenyl)piperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+533.8；1H NMR(400MHz,DMSO-d6)δ7.86(s,1H),7.75(d,J＝3.4Hz,1H),7.56–7.24(m,4H),7.13(t,J＝8.6Hz,1H),6.38(dd,J＝3.4,1.1Hz,1H),4.33(t,J＝6.7Hz,2H),3.07(s,4H),2.66(s,6H),2.40(s,3H).
实施例六十六2-氨基-8-(2-(4-(2-甲氧基嘧啶-5-基)哌嗪-1-基)乙基)-4-(5-甲 基呋喃-2-基)蝶呤-7(8H)-酮
(2-Amino-8-(2-(4-(2-methoxypyrimidin-5-yl)piperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)pteridin-7(8H)-one)
路线参照实施例19。
ESI(m/z):[M+1]+463.8；1H NMR(400MHz,DMSO-d6)δ8.18(s,2H),7.85(s,1H),7.74(d,J＝3.3Hz,1H),7.42(s,2H),6.38(dd,J＝3.4,1.1Hz,1H),4.34(t,J＝6.7Hz,2H),3.76(s,3H),3.60–3.49(m,4H),2.63(t,J＝6.7Hz,2H),2.55(t,J＝4.9Hz,4H),2.40(s,3H).
实施例六十七2-氨基-8-(2-(4-(5-(二氟甲氧基)-3-氟吡啶-2-基)哌嗪-1-基)乙 基)-4-(5-甲基呋喃-2-基)-6-(三氟甲基)蝶呤-7(8H)-酮
(2-Amino-8-(2-(4-(5-(difluoromethoxy)-3-fluoropyridin-2-yl)piperazin-1-yl)ethyl)-4-(5-methylfuran-2-yl)-6-(trifluoromethyl)pteridin-7(8H)-one)
路线参照实施例47。
ESI(m/z):[M+1]+584.8；1H NMR(400MHz,DMSO-d6)δ8.04(s,1H),7.97(d,J＝2.4Hz,1H),7.78(d,J＝3.4Hz,2H),7.60(dd,J＝13.3,2.4Hz,1H),7.14(t,J＝73.7Hz,1H),6.45(dd,J＝3.5,1.1Hz,1H),4.36(t,J＝6.8Hz,2H),3.30(s,4H),2.64(s,6H),2.41(s,3H).
实施例六十八2-氨基-4-(5-甲基呋喃-2-基)-8-(2-(4-(4-苯氧基苯基)哌嗪-1- 基)乙基)蝶呤-7(8H)-酮
(2-amino-4-(5-methylfuran-2-yl)-8-(2-(4-(4-phenoxyphenyl)piperazin-1-yl)ethyl)pteridin-7(8H)-one)
路线参照实施例47。
ESI(m/z):[M+1]+524.2；1H NMR(400MHz,DMSO-d6)δ7.86(s,1H),7.75(d,J＝3.3Hz,1H),7.44(brs,2H),7.34–7.30(m,2H),7.04(t,J＝7.4Hz,1H),6.98–6.83(m,6H),6.38(dd,J＝3.4,0.9Hz,1H),4.34(t,J＝6.7Hz,2H),3.03(s,4H),2.65(s,6H),2.39(s,3H).
实施例六十九化合物对A2AR-cAMP信号通路的抑制活性测试
在诱导表达人腺苷2A受体(A2AR)的HEK-293细胞上进行拮抗剂cAMP抑制功能的活性测定(上海睿智化学研究有限公司，ChemPartner)。将细胞以每孔1000至2500个细胞的密度接种到白色的384孔板中，然后与各种浓度的化合物(范围从1μM到0.46nM，三倍稀释)在37℃孵育60分钟。
a)通过Echo技术将化合物转移至测定板(化合物总体积为100nL)；
b)用刺激缓冲液收集细胞：从烧瓶中取出培养基，然后用5mL PBS洗涤细胞；吸出PBS，加入1.5mL versene，并在37℃孵育2-5分钟；加入4mL培养基并离心，然后使用刺激缓冲液将细胞悬液调节至适当的密度；使用50μL的细胞悬液进行细胞计数；
c)反应：将NECA(购于Sigma Aldrich)以1：2稀释到细胞刺激混合物中，以600rpm的转速离心3分钟，然后在室温下孵育60分钟。孵育60分钟后，加入5μLΜLight-anti-cAMP(由Perkin Elmer提供)和5μL Eu-cAMP示踪剂(由Perkin Elmer提供)。以600rpm的转速离心3分钟，然后在室温下孵育60分钟；
d)读取数值：使用装有615nm激发滤光片和655nm发射滤光片的Envision多标签读板器(由Perkin Elmer提供)检测FRET信号。
使用GraphPad Prism(7.02版)进行数据分析以确定被测化合物的IC50值。
测定结果见表二。
表二、实施例化合物的A2AR cAMP抑制活性(IC50，nM)
表二中：++++表示小于10nM；+++表示IC50大于等于10nM且小于100nM；++表示IC50大于等于100nM且小于1000nM；+表示IC50大于等于1000nM；在40nMNECA浓度下测定。
实验结果表明，本发明的化合物对A2AR-cAMP信号通路有较好的抑制活性。
实施例七十化合物在不同NECA浓度下对A2AR-cAMP的抑制活性测试
在诱导表达人腺苷2A受体(A2AR)的HEK-293细胞上进行模拟肿瘤微环境下化合物对cAMP功能的抑制活性测定(上海睿智化学研究有限公司，ChemPartner)。将细胞以每孔1000至2500个细胞的密度接种到白色的384孔板中，然后与各种浓度的化合物(范围从1μM到0.46nM，三倍稀释)在37℃孵育60分钟。
a)通过Echo技术将化合物转移至测定板(化合物总体积为100nL)；b)用刺激缓冲液收集细胞：从烧瓶中取出培养基，然后用5mL PBS洗涤细胞；吸出PBS，加入1.5mLversene，并在37℃孵育2-5分钟；加入4mL培养基并离心，然后使用刺激缓冲液将细胞悬液调节至适当的密度；使用50μL的细胞悬液进行细胞计数。c)反应：将不同浓度(40nM～5000nM)的NECA(购于Sigma Aldrich)以1：2稀释到细胞刺激混合物中，以600rpm的转速离心3分钟，然后在室温下孵育60分钟。孵育60分钟后，加入5μLΜLight-anti-cAMP(由PerkinElmer提供)和5μL Eu-cAMP示踪剂(由Perkin Elmer提供)。以600rpm的转速离心3分钟，然后在室温下孵育60分钟。d)读取数值：使用装有615nm激发滤光片和655nm发射滤光片的Envision多标签读板器(由Perkin Elmer提供)检测FRET信号。
使用GraphPad Prism(7.02版)进行数据分析以确定被测化合物的IC50值。
测定结果见表三、表四。
表三、实施例47在不同NECA浓度下的A2AR cAMP抑制活性
表四、实施例54在不同NECA浓度下的A2AR cAMP抑制活性
实验结果表明，本发明的实施例47和54化合物在模拟肿瘤微环境的高NECA浓度的条件下对A2AR-cAMP信号通路具有较好的抑制活性，预示着在癌症免疫治疗中更有价值的应用。
以上所述实施例仅表达了本发明的几种实施方式，其描述较为具体和详细，但并不能因此而理解为对本发明专利范围的限制，应当指出的是，对于本领域的技术人员来说，在不脱离本发明构思的前提下，还可以做出若干变形和改造，这些都属于本发明的保护范围，因此，本发明专利的保护范围以所附权利要求为准。
Claims (7)
1.一种通式(I)所示的化合物或其药学上可接受的盐或其立体异构体，
其中
X选自O；
L选自C1-4亚烷基；
A选自共价键，或者/>
B选自甲基，C3-C6环烷基，苯基，吡啶基，呋喃基，嘧啶基；
C选自苯基，呋喃基，吡唑基；
R1选自氢，卤素，氰基，三氟甲基，三氟甲氧基，二氟甲氧基，C1-8烷基，-O-C1-8烷基，-O-G1-O-C1-8烷基，-G1-O-四氢呋喃基，或者-O-苯基中的一种或数种；
R2选自氢，氰基或甲基中的一种或数种；
R3选自氢，甲基或三氟甲基；
R5、R6各自独立地选自氢，甲基，乙基，或者R5与R6桥接为亚甲基或亚乙基；
R7选自氢或甲基；
G1选自C1-4亚烷基；
n1、n2选自0，1，2，3；
n3、n4选自1，2，3。
2.根据权利要求1所述通式(I)所示的化合物或其药学上可接受的盐或其立体异构体，其特征在于，A选自共价键，
3.根据权利要求1所述的化合物或其药学上可接受的盐或其立体异构体，包括：
4.一种药物组合物，其特征在于，包含根据权利要求1至3中任一项所述的化合物或其药学上可接受的盐或其立体异构体，以及药学上可接受的载体。
5.权利要求1至3中任一项所述的化合物或其药学上可接受的盐或其立体异构体，或权利要求4中所述的药物组合物，在制备腺苷A2A受体抑制剂中的应用。
6.权利要求1至3中任一项所述的化合物或其药学上可接受的盐或其立体异构体，或权利要求4中所述的药物组合物，在制备用于治疗或预防与A2AR有关的疾病的药物中的用途。
7.如权利要求6所述的用途，其特征在于，所述疾病为癌症、帕金森病、肌萎缩性侧束硬化症、冠状动脉疾病、轻度认知障碍、多发性硬化、心包性假性肝硬变、类风湿性关节炎、双相型障碍、实验性内毒素血症、及精神分裂症或前述疾病组合。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111514246.7A CN114276349B (zh) | 2021-12-13 | 2021-12-13 | 2-氨基喋啶酮类衍生物或其盐及其制备方法和用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111514246.7A CN114276349B (zh) | 2021-12-13 | 2021-12-13 | 2-氨基喋啶酮类衍生物或其盐及其制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114276349A CN114276349A (zh) | 2022-04-05 |
| CN114276349B true CN114276349B (zh) | 2024-04-09 |
Family
ID=80872135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111514246.7A Active CN114276349B (zh) | 2021-12-13 | 2021-12-13 | 2-氨基喋啶酮类衍生物或其盐及其制备方法和用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114276349B (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102421779A (zh) * | 2010-03-19 | 2012-04-18 | 江苏恒瑞医药股份有限公司 | 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 |
| CN111217815A (zh) * | 2018-11-27 | 2020-06-02 | 沈阳药科大学 | 含有喋啶酮骨架的化合物及其制备方法和应用 |
-
2021
- 2021-12-13 CN CN202111514246.7A patent/CN114276349B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102421779A (zh) * | 2010-03-19 | 2012-04-18 | 江苏恒瑞医药股份有限公司 | 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 |
| CN111217815A (zh) * | 2018-11-27 | 2020-06-02 | 沈阳药科大学 | 含有喋啶酮骨架的化合物及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114276349A (zh) | 2022-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111094253B (zh) | 1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮类似物 | |
| TWI791511B (zh) | 細胞凋亡誘導劑 | |
| TW202309027A (zh) | 作為ｐａｒｐ抑制劑的化合物 | |
| EP2121692B1 (en) | Substituted heterocycles as janus kinase inhibitors | |
| CN104768952B (zh) | PI3Kδ抑制剂 | |
| CA2939219C (en) | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease | |
| RU2633694C2 (ru) | Дейтерированный фениламинопиримидин и фармацевтическая композиция, содержащая такое соединение | |
| EP2755976B1 (en) | 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors | |
| KR20190016976A (ko) | Pi3k 베타 저해제로서의 아자벤즈이미다졸 유도체 | |
| KR20120130294A (ko) | 비시클릭 화합물 및 이중 ｃ―ｓｒｃ／ｊａｋ 억제제로서의 그의 용도 | |
| JP5728499B2 (ja) | タンパク質キナーゼ阻害剤としての化合物および組成物 | |
| JP2006520397A (ja) | 新規融合トリアゾロン類及びその使用 | |
| CN104470934A (zh) | 蛋白激酶抑制剂 | |
| CN104837844A (zh) | 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪 | |
| CN111440161B (zh) | 一种具有par4拮抗活性的二环杂芳基类化合物及其应用 | |
| JP4724366B2 (ja) | アデノシン受容体リガンドとして有用なトリアゾロ−キノリン誘導体 | |
| RU2489432C2 (ru) | ТРИАЗОЛО[1,5-a]ХИНОЛИНЫ В КАЧЕСТВЕ ЛИГАНДОВ РЕЦЕПТОРА АДЕНОЗИНА А3 | |
| JP2017513880A (ja) | ホスファチジルイノシトール３−キナーゼ阻害薬としてのアミノピリジン誘導体 | |
| CN114276349B (zh) | 2-氨基喋啶酮类衍生物或其盐及其制备方法和用途 | |
| US20130324526A1 (en) | [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase | |
| KR20230011981A (ko) | 치환된 트리사이클릭 아미드, 이의 유사체, 및 이를 사용하는 방법 | |
| CN114634521A (zh) | Dna-pk选择性抑制剂及其制备方法和用途 | |
| TWI793877B (zh) | 作為甘油二酯激酶抑制劑的雜環化合物及其用途 | |
| CN117924258A (zh) | 一种吡啶酮类化合物衍生物及其应用 | |
| WO2023178035A1 (en) | Multicyclic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |